Pulmonary Disease, Chronic ObstructivePhase 3NCT01126437

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

A Phase 3 study testing tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day) and tiotropium 2.5 mcg (2 actuations/day) in people with Pulmonary Disease, Chronic Obstructive, run by Boehringer Ingelheim at 1,191 sites in 51 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies. Therefore, prospective data from a trial of adequate size and duration is required to establish that compared to tiotropium HandiHaler®, tiotropium Respimat® will have (a)… Read more about this study

Who is it for?: Ages 40 years and older
Conditions the study is for: Pulmonary Disease, Chronic Obstructive
What is being tested?: tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day) and tiotropium 2.5 mcg (2 actuations/day)
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 17,183 participants
Where: 1,191 sitesin 51 countries
Study dates: May 2010to May 2013
Phase: Phase 3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 40 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

All patients must sign an informed consent consistent with International Conference on Harmonization Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions.
Male or female patients 40 years of age or older.
Patients must be current or ex-smokers with a smoking history of ≥10 pack-years. (Patients who have never smoked cigarettes must be excluded)
All patients must have a diagnosis of COPD (P06-12085), and must meet the following criteria: Relatively stable airway obstruction with a post-bronchodilator FEV1 ≤ 70% of predicted normal and post-bronchodilator FEV1 / FVC ≤70%.
Pulmonary function tests (PFTs) were conducted after the inhalation of 400 μg salbutamol / albuterol (preferred), however testing with either 200 μg salbutamol/albuterol or a combination of salbutamol / albuterol with ipratropium bromide (2 to 4 actuations) was acceptable. Other short-acting beta agonists, such as terbutaline, may have been used for the testing. The medication used for the testing was documented. Further, historical data from measurements within the past 6 months either at the site or at a referral site may have been used (see Section 6.2.1 of the CTP, located in Appendix 16.1.1). Subjects were not to have been randomized to the study without the availability of spirometry data at the actual study site.
Eligibility for PFT sub-study: For subjects participating in the spirometry sub-study, historical data may not have been used for inclusion. These subjects must have qualified in the clinic at Visit 1 after performing a baseline measurement. These subjects performed a pre-dose PFT which was followed by the administration of 400 μg salbutamol / albuterol only (no other short-acting beta agonist was allowed), followed by a post-dose PFT for qualification.
Able to inhale from the HandiHaler® and the Respimat® devices.

Who cannot join

Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence the patients ability to participate in the study.
Patients with a recent history (i.e., six months or less) of myocardial infarction.
Patients with any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year.
Hospitalisation for cardiac failure (New York Heart Association (NYHA) Class III or IV) during the past year.
Known active tuberculosis.
Patients with a history of asthma, cystic fibrosis, clinically evident bronchiectasis, interstitial lung disease, or pulmonary thromboembolic disease.

Show all 22Show fewer

History of thoracotomy with pulmonary resection. Subjects with a history of thoracotomy for other reasons were to have been evaluated per exclusion criterion 1.
Subject was planning to undergo lung transplant or lung volume reduction surgery (LVRS).
Malignancy for which the subject had undergone resection, radiation, chemotherapy or biological treatments within the last 5 years. Subjects with treated basal cell carcinoma were allowed.
Known respiratory infection or exacerbation of COPD in the 4 weeks prior to randomization.
Known hypersensitivity to anticholinergic drugs, lactose, benzalkonium chloride (BAC), ethylenediaminetetraacetic acid (EDTA), or any other components of the HandiHaler® or Respimat® inhalation solution delivery system.
Known moderate to severe renal impairment (as judged by the investigator).
Known narrow angle glaucoma.
Known significant symptomatic prostatic hyperplasia or bladder-neck obstruction. Subjects whose symptoms were controlled on treatment may have been included.
Use of systemic corticosteroid medication at unstable doses (i.e., less than 6 weeks on stable dose) or at doses in excess of the equivalent of 10 mg prednisolone per day.
Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception for at least 3 months prior to and for the duration of the trial.
Significant alcohol or drug abuse within the past 12 months.
Subjects requiring the use of supplemental oxygen therapy for > 12 hours per day.
Subjects who had completed a pulmonary rehabilitation program in the 6 weeks prior to the screening visit or subjects who were currently in a pulmonary rehabilitation program that was not maintained throughout the duration of the study.
Subjects who had taken an investigational drug within 30 days prior to the Screening Visit.
Previous participation (receipt of randomized treatment) in this study.
Subjects who were currently participating in an interventional study.

Trial locations and contacts

1,191 sites in 51 countries.

Country

City, postcode or hospital

1188 sites in 51 countries

United States300 sites

205.452.01079 Boehringer Ingelheim Investigational Site
Abingdon, Virginia
205.452.01061 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico
205.452.01167 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico
205.452.01234 Boehringer Ingelheim Investigational Site
Alexandria, Virginia
205.452.01002 Boehringer Ingelheim Investigational Site
Altoona, Pennsylvania
205.452.01302 Boehringer Ingelheim Investigational Site
Anaheim, California
205.452.01070 Boehringer Ingelheim Investigational Site
Anchorage, Alaska
205.452.01340 Boehringer Ingelheim Investigational Site
Anderson, South Carolina
205.452.01270 Boehringer Ingelheim Investigational Site
Ann Arbor, Michigan
205.452.01096 Boehringer Ingelheim Investigational Site
Arlington, Texas
205.452.01330 Boehringer Ingelheim Investigational Site
Arlington Heights, Illinois
205.452.01271 Boehringer Ingelheim Investigational Site
Asheville, North Carolina
205.452.01266 Boehringer Ingelheim Investigational Site
Ashland, Oregon
205.452.01107 Boehringer Ingelheim Investigational Site
Athens, Alabama
205.452.01130 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
205.452.01364 Boehringer Ingelheim Investigational Site
Auburn, Maine
205.452.01047 Boehringer Ingelheim Investigational Site
Austell, Georgia
205.452.01053 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
205.452.01169 Boehringer Ingelheim Investigational Site
Bangor, Maine
205.452.01159 Boehringer Ingelheim Investigational Site
Bayside, New York
205.452.01354 Boehringer Ingelheim Investigational Site
Beaver, Pennsylvania
205.452.01248 Boehringer Ingelheim Investigational Site
Belleville, Illinois
205.452.01150 Boehringer Ingelheim Investigational Site
Bellevue, Nebraska
205.452.01083 Boehringer Ingelheim Investigational Site
Bend, Oregon
205.452.01349 Boehringer Ingelheim Investigational Site
Benzonia, Michigan
205.452.01022 Boehringer Ingelheim Investigational Site
Biddeford, Maine
205.452.01226 Boehringer Ingelheim Investigational Site
Billings, Montana
205.452.01023 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01035 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01052 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01219 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01227 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01280 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01165 Boehringer Ingelheim Investigational Site
Boise, Idaho
205.452.01063 Boehringer Ingelheim Investigational Site
Bowling Green, Kentucky
205.452.01126 Boehringer Ingelheim Investigational Site
Brentwood, Tennessee
205.452.01163 Boehringer Ingelheim Investigational Site
Bronxville, New York
205.452.01347 Boehringer Ingelheim Investigational Site
Brownsburg, Indiana
205.452.01101 Boehringer Ingelheim Investigational Site
Burlington, North Carolina
205.452.01076 Boehringer Ingelheim Investigational Site
Butte, Montana
205.452.01264 Boehringer Ingelheim Investigational Site
Calabash, North Carolina
205.452.01193 Boehringer Ingelheim Investigational Site
Canal Fulton, Ohio
205.452.01143 Boehringer Ingelheim Investigational Site
Carnegie, Pennsylvania
205.452.01374 Boehringer Ingelheim Investigational Site
Centerville, Ohio
205.452.01218 Boehringer Ingelheim Investigational Site
Chandler, Arizona
205.452.01066 Boehringer Ingelheim Investigational Site
Charleston, South Carolina
205.452.01168 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina
205.452.01205 Boehringer Ingelheim Investigational Site
Chaska, Minnesota
205.452.01220 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee
205.452.01324 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee
205.452.01365 Boehringer Ingelheim Investigational Site
Chelsea, Michigan
205.452.01149 Boehringer Ingelheim Investigational Site
Chesterfield, Michigan
205.452.01014 Boehringer Ingelheim Investigational Site
Chesterfield, Missouri
205.452.01278 Boehringer Ingelheim Investigational Site
Chicago, Illinois
205.452.01006 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
205.452.01373 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
205.452.01011 Boehringer Ingelheim Investigational Site
Clearwater, Florida
205.452.01314 Boehringer Ingelheim Investigational Site
Cleveland, Ohio
205.452.01059 Boehringer Ingelheim Investigational Site
Coeur d'Alene, Idaho
205.452.01049 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado
205.452.01245 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado
205.452.01217 Boehringer Ingelheim Investigational Site
Columbia, South Carolina
205.452.01255 Boehringer Ingelheim Investigational Site
Columbus, Georgia
205.452.01210 Boehringer Ingelheim Investigational Site
Columbus, Ohio
205.452.01232 Boehringer Ingelheim Investigational Site
Columbus, Ohio
205.452.01012 Boehringer Ingelheim Investigational Site
Conyers, Georgia
205.452.01194 Boehringer Ingelheim Investigational Site
Cooperstown, New York
205.452.01050 Boehringer Ingelheim Investigational Site
Corsicana, Texas
205.452.01189 Boehringer Ingelheim Investigational Site
Corvallis, Oregon
205.452.01284 Boehringer Ingelheim Investigational Site
Council Bluffs, Iowa
205.452.01267 Boehringer Ingelheim Investigational Site
Cranston, Rhode Island
205.452.01233 Boehringer Ingelheim Investigational Site
Dallas, Texas
205.452.01334 Boehringer Ingelheim Investigational Site
Dallas, Texas
205.452.01199 Boehringer Ingelheim Investigational Site
Danbury, Connecticut
205.452.01065 Boehringer Ingelheim Investigational Site
Danville, Virginia
205.452.01285 Boehringer Ingelheim Investigational Site
Danville, Virginia
205.452.01309 Boehringer Ingelheim Investigational Site
Dayton, Ohio
205.452.01140 Boehringer Ingelheim Investigational Site
Delaware, Ohio
205.452.01351 Boehringer Ingelheim Investigational Site
Denver, Colorado
205.452.01146 Boehringer Ingelheim Investigational Site
Detroit, Michigan
205.452.01371 Boehringer Ingelheim Investigational Site
Downer Grove, Illinois
205.452.01320 Boehringer Ingelheim Investigational Site
Downingtown, Pennsylvania
205.452.01021 Boehringer Ingelheim Investigational Site
Dubuque, Iowa
205.452.01062 Boehringer Ingelheim Investigational Site
Eagle, Idaho
205.452.01303 Boehringer Ingelheim Investigational Site
Easley, South Carolina
205.452.01211 Boehringer Ingelheim Investigational Site
Edina, Minnesota
205.452.01108 Boehringer Ingelheim Investigational Site
Elizabeth City, North Carolina
205.452.01190 Boehringer Ingelheim Investigational Site
Elkridge, Maryland
205.452.01131 Boehringer Ingelheim Investigational Site
Elmira, New York
205.452.01038 Boehringer Ingelheim Investigational Site
Encinitas, California
205.452.01142 Boehringer Ingelheim Investigational Site
Endwell, New York
205.452.01323 Boehringer Ingelheim Investigational Site
Erie, Pennsylvania
205.452.01045 Boehringer Ingelheim Investigational Site
Ettrick, Virginia
205.452.01153 Boehringer Ingelheim Investigational Site
Evansville, Indiana
205.452.01366 Boehringer Ingelheim Investigational Site
Fall River, Massachusetts
205.452.01301 Boehringer Ingelheim Investigational Site
Fishers, Indiana
205.452.01198 Boehringer Ingelheim Investigational Site
Florence, Alabama
205.452.01259 Boehringer Ingelheim Investigational Site
Florence, South Carolina
205.452.01018 Boehringer Ingelheim Investigational Site
Fort Collins, Colorado
205.452.01206 Boehringer Ingelheim Investigational Site
Fort Mitchell, Kentucky
205.452.01057 Boehringer Ingelheim Investigational Site
Fort Worth, Texas
205.452.01181 Boehringer Ingelheim Investigational Site
Fort Worth, Texas
205.452.01272 Boehringer Ingelheim Investigational Site
Fort Worth, Texas
205.452.01313 Boehringer Ingelheim Investigational Site
Fountain Valley, California
205.452.01375 Boehringer Ingelheim Investigational Site
Fountain Valley, California
205.452.01141 Boehringer Ingelheim Investigational Site
Franklin, Indiana
205.452.01187 Boehringer Ingelheim Investigational Site
Fremont, Nebraska
205.452.01104 Boehringer Ingelheim Investigational Site
Fridley, Minnesota
205.452.01074 Boehringer Ingelheim Investigational Site
Fullerton, California
205.452.01013 Boehringer Ingelheim Investigational Site
Gaffney, South Carolina
205.452.01299 Boehringer Ingelheim Investigational Site
Gainesville, Georgia
205.452.01192 Boehringer Ingelheim Investigational Site
Glens Falls, New York
205.452.01279 Boehringer Ingelheim Investigational Site
Great Neck, New York
205.452.01033 Boehringer Ingelheim Investigational Site
Greensboro, North Carolina
205.452.01172 Boehringer Ingelheim Investigational Site
Greensboro, North Carolina
205.452.01077 Boehringer Ingelheim Investigational Site
Greenville, South Carolina
205.452.01093 Boehringer Ingelheim Investigational Site
Greer, South Carolina
205.452.01054 Boehringer Ingelheim Investigational Site
Hartford, Connecticut
205.452.01269 Boehringer Ingelheim Investigational Site
Haverhill, Massachusetts
205.452.01166 Boehringer Ingelheim Investigational Site
Hayden Lake, Idaho
205.452.01073 Boehringer Ingelheim Investigational Site
Henderson, Nevada
205.452.01209 Boehringer Ingelheim Investigational Site
Hialeah, Florida
205.452.01098 Boehringer Ingelheim Investigational Site
Hickory, North Carolina
205.452.01115 Boehringer Ingelheim Investigational Site
Hickory, North Carolina
205.452.01295 Boehringer Ingelheim Investigational Site
Hodges, South Carolina
205.452.01336 Boehringer Ingelheim Investigational Site
Hollywood, Maryland
205.452.01360 Boehringer Ingelheim Investigational Site
Homestead, Florida
205.452.01328 Boehringer Ingelheim Investigational Site
Honeoye Falls, New York
205.452.01100 Boehringer Ingelheim Investigational Site
Honolulu, Hawaii
205.452.01082 Boehringer Ingelheim Investigational Site
Houston, Texas
205.452.01105 Boehringer Ingelheim Investigational Site
Houston, Texas
205.452.01178 Boehringer Ingelheim Investigational Site
Houston, Texas
205.452.01212 Boehringer Ingelheim Investigational Site
Houston, Texas
205.452.01139 Boehringer Ingelheim Investigational Site
Interlochen, Michigan
205.452.01241 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
205.452.01337 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
205.452.01343 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
205.452.01257 Boehringer Ingelheim Investigational Site
Jefferson Hills, Pennsylvania
205.452.01214 Boehringer Ingelheim Investigational Site
Johnston, Rhode Island
205.452.01184 Boehringer Ingelheim Investigational Site
Jupiter, Florida
205.452.01080 Boehringer Ingelheim Investigational Site
Kalamazoo, Michigan
205.452.01342 Boehringer Ingelheim Investigational Site
Kingsport, Tennessee
205.452.01137 Boehringer Ingelheim Investigational Site
Lafayette, Indiana
205.452.01015 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana
205.452.01345 Boehringer Ingelheim Investigational Site
Lancaster, California
205.452.01332 Boehringer Ingelheim Investigational Site
Langhorne, Pennsylvania
205.452.01305 Boehringer Ingelheim Investigational Site
Lansing, Kansas
205.452.01031 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada
205.452.01261 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada
205.452.01288 Boehringer Ingelheim Investigational Site
Lawrenceville, Georgia
205.452.01026 Boehringer Ingelheim Investigational Site
Lebanon, New Hampshire
205.452.01171 Boehringer Ingelheim Investigational Site
Lincoln, California
205.452.01235 Boehringer Ingelheim Investigational Site
Lombard, Illinois
205.452.01339 Boehringer Ingelheim Investigational Site
Lomita, California
205.452.01274 Boehringer Ingelheim Investigational Site
Longview, Texas
205.452.01298 Boehringer Ingelheim Investigational Site
Los Angeles, California
205.452.01356 Boehringer Ingelheim Investigational Site
Los Angeles, California
205.452.01289 Boehringer Ingelheim Investigational Site
Louisville, Kentucky
205.452.01030 Boehringer Ingelheim Investigational Site
Lynchburg, Virginia
205.452.01116 Boehringer Ingelheim Investigational Site
McKinney, Texas
205.452.01275 Boehringer Ingelheim Investigational Site
Meridian, Idaho
205.452.01175 Boehringer Ingelheim Investigational Site
Mesa, Arizona
205.452.01200 Boehringer Ingelheim Investigational Site
Mesa, Arizona
205.452.01317 Boehringer Ingelheim Investigational Site
Mesa, Arizona
205.452.01138 Boehringer Ingelheim Investigational Site
Miami, Florida
205.452.01246 Boehringer Ingelheim Investigational Site
Miami, Florida
205.452.01321 Boehringer Ingelheim Investigational Site
Miami, Florida
205.452.01223 Boehringer Ingelheim Investigational Site
Midvale, Utah
205.452.01113 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota
205.452.01196 Boehringer Ingelheim Investigational Site
Missoula, Montana
205.452.01244 Boehringer Ingelheim Investigational Site
Mobile, Alabama
205.452.01041 Boehringer Ingelheim Investigational Site
Montgomery, Alabama
205.452.01263 Boehringer Ingelheim Investigational Site
Muncie, Indiana
205.452.01335 Boehringer Ingelheim Investigational Site
Myrtle Beach, South Carolina
205.452.01208 Boehringer Ingelheim Investigational Site
New Bedford, Massachusetts
205.452.01290 Boehringer Ingelheim Investigational Site
New Port Richey, Florida
205.452.01118 Boehringer Ingelheim Investigational Site
New Windsor, New York
205.452.01127 Boehringer Ingelheim Investigational Site
New York, New York
205.452.01308 Boehringer Ingelheim Investigational Site
Newark, Delaware
205.452.01369 Boehringer Ingelheim Investigational Site
Newington, New Hampshire
205.452.01075 Boehringer Ingelheim Investigational Site
Norristown, Pennsylvania
205.452.01072 Boehringer Ingelheim Investigational Site
Norwalk, Connecticut
205.452.01180 Boehringer Ingelheim Investigational Site
O'Fallon, Illinois
205.452.01268 Boehringer Ingelheim Investigational Site
Oak Park, Illinois
205.452.01203 Boehringer Ingelheim Investigational Site
Ocala, Florida
205.452.01296 Boehringer Ingelheim Investigational Site
Ocean City, New Jersey
205.452.01010 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma
205.452.01094 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma
205.452.01304 Boehringer Ingelheim Investigational Site
Olathe, Kansas
205.452.01019 Boehringer Ingelheim Investigational Site
Olive Branch, Mississippi
205.452.01155 Boehringer Ingelheim Investigational Site
Omaha, Nebraska
205.452.01148 Boehringer Ingelheim Investigational Site
Orange, California
205.452.01201 Boehringer Ingelheim Investigational Site
Oregon, Wisconsin
205.452.01174 Boehringer Ingelheim Investigational Site
Orlando, Florida
205.452.01135 Boehringer Ingelheim Investigational Site
Ormond Beach, Florida
205.452.01125 Boehringer Ingelheim Investigational Site
Overland Park, Kansas
205.452.01173 Boehringer Ingelheim Investigational Site
Oviedo, Florida
205.452.01152 Boehringer Ingelheim Investigational Site
Paducah, Kentucky
205.452.01111 Boehringer Ingelheim Investigational Site
Palm Springs, California
205.452.01195 Boehringer Ingelheim Investigational Site
Panama City, Florida
205.452.01197 Boehringer Ingelheim Investigational Site
Panama City, Florida
205.452.01147 Boehringer Ingelheim Investigational Site
Paramount, California
205.452.01239 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida
205.452.01247 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida
205.452.01286 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida
205.452.01240 Boehringer Ingelheim Investigational Site
Pensacola, Florida
205.452.01350 Boehringer Ingelheim Investigational Site
Pheonix, Arizona
205.452.01087 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania
205.452.01144 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania
205.452.01254 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
205.452.01283 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
205.452.01003 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania
205.452.01361 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania
205.452.01036 Boehringer Ingelheim Investigational Site
Pleasant Hills, Pennsylvania
205.452.01260 Boehringer Ingelheim Investigational Site
Ponte Vedra, Florida
205.452.01071 Boehringer Ingelheim Investigational Site
Poway, California
205.452.01359 Boehringer Ingelheim Investigational Site
Quincy, Illinois
205.452.01128 Boehringer Ingelheim Investigational Site
Raleigh, North Carolina
205.452.01089 Boehringer Ingelheim Investigational Site
Rancho Cucamonga, California
205.452.01004 Boehringer Ingelheim Investigational Site
Rapid City, South Dakota
205.452.01097 Boehringer Ingelheim Investigational Site
Redlands, California
205.452.01262 Boehringer Ingelheim Investigational Site
Richardson, Texas
205.452.01016 Boehringer Ingelheim Investigational Site
Richmond, Virginia
205.452.01039 Boehringer Ingelheim Investigational Site
Richmond, Virginia
205.452.01044 Boehringer Ingelheim Investigational Site
Richmond, Virginia
205.452.01300 Boehringer Ingelheim Investigational Site
Richmond, Virginia
205.452.01042 Boehringer Ingelheim Investigational Site
Rochester, Minnesota
205.452.01058 Boehringer Ingelheim Investigational Site
Rochester, New York
205.452.01056 Boehringer Ingelheim Investigational Site
Rock Hill, South Carolina
205.452.01092 Boehringer Ingelheim Investigational Site
Rockledge, Florida
205.452.01352 Boehringer Ingelheim Investigational Site
Rocky Mount, North Carolina
205.452.01129 Boehringer Ingelheim Investigational Site
Saint Charles, Missouri
205.452.01348 Boehringer Ingelheim Investigational Site
Salisbury, North Carolina
205.452.01001 Boehringer Ingelheim Investigational Site
Salt Lake City, Utah
205.452.01055 Boehringer Ingelheim Investigational Site
San Antonio, Texas
205.452.01182 Boehringer Ingelheim Investigational Site
San Antonio, Texas
205.452.01186 Boehringer Ingelheim Investigational Site
San Antonio, Texas
205.452.01353 Boehringer Ingelheim Investigational Site
San Antonio, Texas
205.452.01078 Boehringer Ingelheim Investigational Site
San Diego, California
205.452.01176 Boehringer Ingelheim Investigational Site
San Diego, California
205.452.01346 Boehringer Ingelheim Investigational Site
San Diego, California
205.452.01306 Boehringer Ingelheim Investigational Site
San Jose, California
205.452.01297 Boehringer Ingelheim Investigational Site
Santa Barbara, California
205.452.01251 Boehringer Ingelheim Investigational Site
Sarasota, Florida
205.452.01099 Boehringer Ingelheim Investigational Site
Selah, Washington
205.452.01091 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana
205.452.01329 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana
205.452.01090 Boehringer Ingelheim Investigational Site
Snellville, Georgia
205.452.01294 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina
205.452.01008 Boehringer Ingelheim Investigational Site
Spokane, Washington
205.452.01069 Boehringer Ingelheim Investigational Site
Spokane, Washington
205.452.01145 Boehringer Ingelheim Investigational Site
Spokane, Washington
205.452.01341 Boehringer Ingelheim Investigational Site
Springfield, Oregon
205.452.01110 Boehringer Ingelheim Investigational Site
St Louis, Missouri
205.452.01133 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
205.452.01136 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
205.452.01207 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
205.452.01040 Boehringer Ingelheim Investigational Site
Stamford, Connecticut
205.452.01032 Boehringer Ingelheim Investigational Site
Statesville, North Carolina
205.452.01310 Boehringer Ingelheim Investigational Site
Stevensville, Michigan
205.452.01215 Boehringer Ingelheim Investigational Site
Sugar Land, Texas
205.452.01084 Boehringer Ingelheim Investigational Site
Sylvania, Ohio
205.452.01085 Boehringer Ingelheim Investigational Site
Syracuse, New York
205.452.01293 Boehringer Ingelheim Investigational Site
Syracuse, New York
205.452.01276 Boehringer Ingelheim Investigational Site
Tabor City, North Carolina
205.452.01185 Boehringer Ingelheim Investigational Site
Tacoma, Washington
205.452.01134 Boehringer Ingelheim Investigational Site
Tamarac, Florida
205.452.01231 Boehringer Ingelheim Investigational Site
Tamarac, Florida
205.452.01025 Boehringer Ingelheim Investigational Site
Tampa, Florida
205.452.01250 Boehringer Ingelheim Investigational Site
Tampa, Florida
205.452.01315 Boehringer Ingelheim Investigational Site
Tempe, Arizona
205.452.01287 Boehringer Ingelheim Investigational Site
Toledo, Ohio
205.452.01046 Boehringer Ingelheim Investigational Site
Toms River, New Jersey
205.452.01068 Boehringer Ingelheim Investigational Site
Topeka, Kansas
205.452.01238 Boehringer Ingelheim Investigational Site
Towson, Maryland
205.452.01243 Boehringer Ingelheim Investigational Site
Towson, Maryland
205.452.01122 Boehringer Ingelheim Investigational Site
Traverse City, Michigan
205.452.01081 Boehringer Ingelheim Investigational Site
Troy, Michigan
205.452.01221 Boehringer Ingelheim Investigational Site
Troy, Michigan
205.452.01158 Boehringer Ingelheim Investigational Site
Tucson, Arizona
205.452.01161 Boehringer Ingelheim Investigational Site
Tucson, Arizona
205.452.01029 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma
205.452.01043 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma
205.452.01362 Boehringer Ingelheim Investigational Site
Tustin, California
205.452.01106 Boehringer Ingelheim Investigational Site
Uniontown, Pennsylvania
205.452.01156 Boehringer Ingelheim Investigational Site
Uniontown, Pennsylvania
205.452.01151 Boehringer Ingelheim Investigational Site
Vestal, New York
205.452.01225 Boehringer Ingelheim Investigational Site
Victorville, California
205.452.01224 Boehringer Ingelheim Investigational Site
Walnut Creek, California
205.452.01204 Boehringer Ingelheim Investigational Site
Warminster, Pennsylvania
205.452.01109 Boehringer Ingelheim Investigational Site
Waterbury, Connecticut
205.452.01007 Boehringer Ingelheim Investigational Site
Wenatchee, Washington
205.452.01344 Boehringer Ingelheim Investigational Site
West Allis, Wisconsin
205.452.01179 Boehringer Ingelheim Investigational Site
West Plains, Missouri
205.452.01188 Boehringer Ingelheim Investigational Site
Westfield, New York
205.452.01005 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
205.452.01024 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
205.452.01236 Boehringer Ingelheim Investigational Site
Wildomar, California
205.452.01157 Boehringer Ingelheim Investigational Site
Wilmington, North Carolina
205.452.01363 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina

Other trials in United States

Germany115 sites

205.452.49096 Boehringer Ingelheim Investigational Site
Aschaffenburg
205.452.49130 Boehringer Ingelheim Investigational Site
Augsburg
205.452.49161 Boehringer Ingelheim Investigational Site
Augsburg
205.452.49001 Boehringer Ingelheim Investigational Site
Backnang
205.452.49173 Boehringer Ingelheim Investigational Site
Bad Kissingen
205.452.49134 Boehringer Ingelheim Investigational Site
Bad Lippspringe
205.452.49082 Boehringer Ingelheim Investigational Site
Bad Neustadt an der Saale
205.452.49058 Boehringer Ingelheim Investigational Site
Bad Wörishofen
205.452.49145 Boehringer Ingelheim Investigational Site
Bamberg
205.452.49072 Boehringer Ingelheim Investigational Site
Bensheim
205.452.49048 Boehringer Ingelheim Investigational Site
Bergisch Gladbach
205.452.49006 Boehringer Ingelheim Investigational Site
Berlin
205.452.49016 Boehringer Ingelheim Investigational Site
Berlin
205.452.49028 Boehringer Ingelheim Investigational Site
Berlin
205.452.49031 Boehringer Ingelheim Investigational Site
Berlin
205.452.49054 Boehringer Ingelheim Investigational Site
Berlin
205.452.49064 Boehringer Ingelheim Investigational Site
Berlin
205.452.49066 Boehringer Ingelheim Investigational Site
Berlin
205.452.49068 Boehringer Ingelheim Investigational Site
Berlin
205.452.49102 Boehringer Ingelheim Investigational Site
Berlin
205.452.49135 Boehringer Ingelheim Investigational Site
Berlin
205.452.49138 Boehringer Ingelheim Investigational Site
Berlin
205.452.49157 Boehringer Ingelheim Investigational Site
Berlin
205.452.49167 Boehringer Ingelheim Investigational Site
Berlin
205.452.49175 Boehringer Ingelheim Investigational Site
Berlin
205.452.49180 Boehringer Ingelheim Investigational Site
Berlin
205.452.49037 Boehringer Ingelheim Investigational Site
Bonn
205.452.49118 Boehringer Ingelheim Investigational Site
Bonn
205.452.49083 Boehringer Ingelheim Investigational Site
Brake
205.452.49040 Boehringer Ingelheim Investigational Site
Bruchsal
205.452.49089 Boehringer Ingelheim Investigational Site
Celle
205.452.49146 Boehringer Ingelheim Investigational Site
Cologne
205.452.49143 Boehringer Ingelheim Investigational Site
Cottbus
205.452.49119 Boehringer Ingelheim Investigational Site
Deggendorf
205.452.49151 Boehringer Ingelheim Investigational Site
Dillingen
205.452.49117 Boehringer Ingelheim Investigational Site
Donaueschingen
205.452.49015 Boehringer Ingelheim Investigational Site
Dortmund
205.452.49008 Boehringer Ingelheim Investigational Site
Düren
205.452.49098 Boehringer Ingelheim Investigational Site
Emden
205.452.49003 Boehringer Ingelheim Investigational Site
Engelskirchen
205.452.49024 Boehringer Ingelheim Investigational Site
Ense
205.452.49168 Boehringer Ingelheim Investigational Site
Essen
205.452.49133 Boehringer Ingelheim Investigational Site
Föhren
205.452.49104 Boehringer Ingelheim Investigational Site
Forchheim
205.452.49070 Boehringer Ingelheim Investigational Site
Frankfurt
205.452.49147 Boehringer Ingelheim Investigational Site
Frankfurt
205.452.49137 Boehringer Ingelheim Investigational Site
Fulda
205.452.49107 Boehringer Ingelheim Investigational Site
Gelnhausen
205.452.49032 Boehringer Ingelheim Investigational Site
Gütersloh
205.452.49026 Boehringer Ingelheim Investigational Site
Hagen
205.452.49041 Boehringer Ingelheim Investigational Site
Hagen
205.452.49044 Boehringer Ingelheim Investigational Site
Hamburg
205.452.49061 Boehringer Ingelheim Investigational Site
Hamburg
205.452.49080 Boehringer Ingelheim Investigational Site
Hamburg
205.452.49038 Boehringer Ingelheim Investigational Site
Hanover
205.452.49052 Boehringer Ingelheim Investigational Site
Hanover
205.452.49094 Boehringer Ingelheim Investigational Site
Hanover
205.452.49181 Boehringer Ingelheim Investigational Site
Heidelberg
205.452.49116 Boehringer Ingelheim Investigational Site
Heilbronn
205.452.49022 Boehringer Ingelheim Investigational Site
Hemmingen
205.452.49007 Boehringer Ingelheim Investigational Site
Höchstädt
205.452.49136 Boehringer Ingelheim Investigational Site
Ingelheim
205.452.49047 Boehringer Ingelheim Investigational Site
Käbschütztal-Krögis
205.452.49159 Boehringer Ingelheim Investigational Site
Karlsruhe
205.452.49027 Boehringer Ingelheim Investigational Site
Kassel
205.452.49105 Boehringer Ingelheim Investigational Site
Kaufbeuren
205.452.49101 Boehringer Ingelheim Investigational Site
Koblenz
205.452.49114 Boehringer Ingelheim Investigational Site
Landsberg am Lech
205.452.49169 Boehringer Ingelheim Investigational Site
Langen
205.452.49017 Boehringer Ingelheim Investigational Site
Leipzig
205.452.49035 Boehringer Ingelheim Investigational Site
Leipzig
205.452.49113 Boehringer Ingelheim Investigational Site
Leipzig
205.452.49139 Boehringer Ingelheim Investigational Site
Leipzig
205.452.49172 Boehringer Ingelheim Investigational Site
Leipzig
205.452.49110 Boehringer Ingelheim Investigational Site
Leonberg
205.452.49088 Boehringer Ingelheim Investigational Site
Mannheim
205.452.49108 Boehringer Ingelheim Investigational Site
Marburg
205.452.49122 Boehringer Ingelheim Investigational Site
Marburg
205.452.49055 Boehringer Ingelheim Investigational Site
Minden
205.452.49025 Boehringer Ingelheim Investigational Site
München
205.452.49131 Boehringer Ingelheim Investigational Site
München
205.452.49023 Boehringer Ingelheim Investigational Site
Neumünster
205.452.49132 Boehringer Ingelheim Investigational Site
Neuruppin
205.452.49045 Boehringer Ingelheim Investigational Site
Neuwied
205.452.49062 Boehringer Ingelheim Investigational Site
Oranienburg
205.452.49124 Boehringer Ingelheim Investigational Site
Oschersleben
205.452.49019 Boehringer Ingelheim Investigational Site
Paderborn
205.452.49053 Boehringer Ingelheim Investigational Site
Potsdam
205.452.49076 Boehringer Ingelheim Investigational Site
Potsdam
205.452.49049 Boehringer Ingelheim Investigational Site
Radebeul
205.452.49056 Boehringer Ingelheim Investigational Site
Rathenow
205.452.49009 Boehringer Ingelheim Investigational Site
Raubach
205.452.49002 Boehringer Ingelheim Investigational Site
Rehau
205.452.49142 Boehringer Ingelheim Investigational Site
Reinfeld
205.452.49030 Boehringer Ingelheim Investigational Site
Rhaunen
205.452.49184 Boehringer Ingelheim Investigational Site
Rheine
205.452.49077 Boehringer Ingelheim Investigational Site
Rodgau-Dudenhofen
205.452.49021 Boehringer Ingelheim Investigational Site
Rüsselsheim am Main
205.452.49091 Boehringer Ingelheim Investigational Site
Rüsselsheim am Main
205.452.49042 Boehringer Ingelheim Investigational Site
Saarlouis
205.452.49034 Boehringer Ingelheim Investigational Site
Schwetzingen
205.452.49013 Boehringer Ingelheim Investigational Site
Solingen
205.452.49057 Boehringer Ingelheim Investigational Site
Solingen
205.452.49078 Boehringer Ingelheim Investigational Site
Tübingen
205.452.49099 Boehringer Ingelheim Investigational Site
Ulm
205.452.49043 Boehringer Ingelheim Investigational Site
Wallerfing
205.452.49067 Boehringer Ingelheim Investigational Site
Wardenburg
205.452.49165 Boehringer Ingelheim Investigational Site
Warendorf
205.452.49051 Boehringer Ingelheim Investigational Site
Weinheim
205.452.49127 Boehringer Ingelheim Investigational Site
Weyhe
205.452.49092 Boehringer Ingelheim Investigational Site
Wiesloch
205.452.49018 Boehringer Ingelheim Investigational Site
Witten
205.452.49029 Boehringer Ingelheim Investigational Site
Witten
205.452.49095 Boehringer Ingelheim Investigational Site
Wolfsburg
205.452.49060 Boehringer Ingelheim Investigational Site
Zerbst

Other trials in Germany

France94 sites

205.452.33087 Boehringer Ingelheim Investigational Site
Albens
205.452.33028 Boehringer Ingelheim Investigational Site
Angers
205.452.33055 Boehringer Ingelheim Investigational Site
Angers
205.452.33142 Boehringer Ingelheim Investigational Site
Angers
205.452.33159 Boehringer Ingelheim Investigational Site
Angers
205.452.33030 Boehringer Ingelheim Investigational Site
Anzin
205.452.33158 Boehringer Ingelheim Investigational Site
Arras
205.452.33084 Boehringer Ingelheim Investigational Site
Avrillé
205.452.33128 Boehringer Ingelheim Investigational Site
Bécon-les-Granits
205.452.33029 Boehringer Ingelheim Investigational Site
Bersée
205.452.33018 Boehringer Ingelheim Investigational Site
Béziers
205.452.33053 Boehringer Ingelheim Investigational Site
Bischheim
205.452.33024 Boehringer Ingelheim Investigational Site
Blois
205.452.33043 Boehringer Ingelheim Investigational Site
Bort-les-Orgues
205.452.33091 Boehringer Ingelheim Investigational Site
Bourg Des Cptes
205.452.33123 Boehringer Ingelheim Investigational Site
Briollay
205.452.33063 Boehringer Ingelheim Investigational Site
Broglie
205.452.33074 Boehringer Ingelheim Investigational Site
Bruay-la-Buissière
205.452.33010 Boehringer Ingelheim Investigational Site
Cannes
205.452.33118 Boehringer Ingelheim Investigational Site
Cannes
205.452.33009 Boehringer Ingelheim Investigational Site
Chamalières
205.452.33073 Boehringer Ingelheim Investigational Site
Chambéry
205.452.33059 Boehringer Ingelheim Investigational Site
Château-Renault
205.452.33089 Boehringer Ingelheim Investigational Site
Colombey-les-Belles
205.452.33099 Boehringer Ingelheim Investigational Site
Cournonterral
205.452.33127 Boehringer Ingelheim Investigational Site
Cournonterral
205.452.33162 Boehringer Ingelheim Investigational Site
Croix
205.452.33105 Boehringer Ingelheim Investigational Site
Dinard
205.452.33110 Boehringer Ingelheim Investigational Site
Donges
205.452.33094 Boehringer Ingelheim Investigational Site
Gambsheim
205.452.33046 Boehringer Ingelheim Investigational Site
Grenoble
205.452.33096 Boehringer Ingelheim Investigational Site
Hautmont
205.452.33090 Boehringer Ingelheim Investigational Site
Hinx
205.452.33145 Boehringer Ingelheim Investigational Site
Jarny
205.452.33154 Boehringer Ingelheim Investigational Site
La Bouëxière
205.452.33065 Boehringer Ingelheim Investigational Site
La Chapelle-sur-Erdre
205.452.33102 Boehringer Ingelheim Investigational Site
La Montagne
205.452.33100 Boehringer Ingelheim Investigational Site
La Riche
205.452.33058 Boehringer Ingelheim Investigational Site
Lambersart
205.452.33098 Boehringer Ingelheim Investigational Site
Lambersart
205.452.33103 Boehringer Ingelheim Investigational Site
Levallois-Perret
205.452.33164 Boehringer Ingelheim Investigational Site
Louvigné-de-Bais
205.452.33111 Boehringer Ingelheim Investigational Site
Luynes
205.452.33136 Boehringer Ingelheim Investigational Site
Marcq-en-Barœul
205.452.33115 Boehringer Ingelheim Investigational Site
Mondelange
205.452.33088 Boehringer Ingelheim Investigational Site
Mont-de-Marsan
205.452.33138 Boehringer Ingelheim Investigational Site
Mont-de-Marsan
205.452.33005 Boehringer Ingelheim Investigational Site
Montigny-lès-Metz
205.452.33163 Boehringer Ingelheim Investigational Site
Mundolsheim
205.452.33109 Boehringer Ingelheim Investigational Site
Mûrs-Erigné
205.452.33031 Boehringer Ingelheim Investigational Site
Nantes
205.452.33003 Boehringer Ingelheim Investigational Site
Nice
205.452.33108 Boehringer Ingelheim Investigational Site
Oignies
205.452.33014 Boehringer Ingelheim Investigational Site
Ollioules
205.452.33157 Boehringer Ingelheim Investigational Site
Orthez
205.452.33112 Boehringer Ingelheim Investigational Site
Parçay-les-Pins
205.452.33001 Boehringer Ingelheim Investigational Site
Paris
205.452.33051 Boehringer Ingelheim Investigational Site
Paris
205.452.33082 Boehringer Ingelheim Investigational Site
Paris
205.452.33165 Boehringer Ingelheim Investigational Site
Paris
205.452.33130 Boehringer Ingelheim Investigational Site
Pont-à-Mousson
205.452.33122 Boehringer Ingelheim Investigational Site
Quarouble
205.452.33006 Boehringer Ingelheim Investigational Site
Reims
205.452.33153 Boehringer Ingelheim Investigational Site
Rosiers-d'Égletons
205.452.33161 Boehringer Ingelheim Investigational Site
Rugles
205.452.33126 Boehringer Ingelheim Investigational Site
Saint-Alban-Leysse
205.452.33140 Boehringer Ingelheim Investigational Site
Saint-Aulaire
205.452.33052 Boehringer Ingelheim Investigational Site
Saint-Avertin
205.452.33160 Boehringer Ingelheim Investigational Site
Saint-Jouan-des-Guérets
205.452.33011 Boehringer Ingelheim Investigational Site
Saint-Léger-des-Bois
205.452.33079 Boehringer Ingelheim Investigational Site
Saint-Sébastien-sur-Loire
205.452.33002 Boehringer Ingelheim Investigational Site
Saintes
205.452.33148 Boehringer Ingelheim Investigational Site
Salies-de-Béarn
205.452.33026 Boehringer Ingelheim Investigational Site
Savonnières
205.452.33067 Boehringer Ingelheim Investigational Site
Segré
205.452.33040 Boehringer Ingelheim Investigational Site
Serres Casset
205.452.33012 Boehringer Ingelheim Investigational Site
Six Four Les Plages
205.452.33007 Boehringer Ingelheim Investigational Site
Strasbourg
205.452.33033 Boehringer Ingelheim Investigational Site
Strasbourg
205.452.33097 Boehringer Ingelheim Investigational Site
Strasbourg
205.452.33101 Boehringer Ingelheim Investigational Site
Strasbourg
205.452.33107 Boehringer Ingelheim Investigational Site
Thouars
205.452.33116 Boehringer Ingelheim Investigational Site
Tinténiac
205.452.33013 Boehringer Ingelheim Investigational Site
Toulon
205.452.33054 Boehringer Ingelheim Investigational Site
Tours
205.452.33064 Boehringer Ingelheim Investigational Site
Tours
205.452.33092 Boehringer Ingelheim Investigational Site
Tours
205.452.33124 Boehringer Ingelheim Investigational Site
Tours
205.452.33066 Boehringer Ingelheim Investigational Site
Vendôme
205.452.33137 Boehringer Ingelheim Investigational Site
Vernoil-le-Fourrier
205.452.33032 Boehringer Ingelheim Investigational Site
Vieux-Condé
205.452.33151 Boehringer Ingelheim Investigational Site
Vihiers
205.452.33077 Boehringer Ingelheim Investigational Site
Villey-Saint-Étienne
205.452.33135 Boehringer Ingelheim Investigational Site
Wattrelos

Other trials in France

Russia56 sites

205.452.07030 Boehringer Ingelheim Investigational Site
Arkhangelsk
205.452.07049 Boehringer Ingelheim Investigational Site
Barnaul
205.452.07054 Boehringer Ingelheim Investigational Site
Barnaul
205.452.07053 Boehringer Ingelheim Investigational Site
Chelyabinsk
205.452.07038 Boehringer Ingelheim Investigational Site
Gatchina (Leningradskaya Oblast)
205.452.07036 Boehringer Ingelheim Investigational Site
Irkutsk
205.452.07001 Boehringer Ingelheim Investigational Site
Ivanovo
205.452.07023 Boehringer Ingelheim Investigational Site
Kaliningrad
205.452.07003 Boehringer Ingelheim Investigational Site
Kazan'
205.452.07005 Boehringer Ingelheim Investigational Site
Kazan'
205.452.07007 Boehringer Ingelheim Investigational Site
Kazan'
205.452.07048 Boehringer Ingelheim Investigational Site
Kemerovo
205.452.07060 Boehringer Ingelheim Investigational Site
Kemerovo
205.452.07059 Boehringer Ingelheim Investigational Site
Kirov
205.452.07009 Boehringer Ingelheim Investigational Site
Krasnodar
205.452.07010 Boehringer Ingelheim Investigational Site
Krasnodar
205.452.07013 Boehringer Ingelheim Investigational Site
Moscow
205.452.07020 Boehringer Ingelheim Investigational Site
Moscow
205.452.07021 Boehringer Ingelheim Investigational Site
Moscow
205.452.07026 Boehringer Ingelheim Investigational Site
Moscow
205.452.07027 Boehringer Ingelheim Investigational Site
Moscow
205.452.07028 Boehringer Ingelheim Investigational Site
Moscow
205.452.07029 Boehringer Ingelheim Investigational Site
Moscow
205.452.07043 Boehringer Ingelheim Investigational Site
Moscow
205.452.07045 Boehringer Ingelheim Investigational Site
Moscow
205.452.07004 Boehringer Ingelheim Investigational Site
Murmansk
205.452.07051 Boehringer Ingelheim Investigational Site
Nizhny Novgorod
205.452.07055 Boehringer Ingelheim Investigational Site
Nizhny Novgorod
205.452.07037 Boehringer Ingelheim Investigational Site
Novosibirsk
205.452.07040 Boehringer Ingelheim Investigational Site
Novosibirsk
205.452.07042 Boehringer Ingelheim Investigational Site
Novosibirsk
205.452.07041 Boehringer Ingelheim Investigational Site
Penza
205.452.07050 Boehringer Ingelheim Investigational Site
Pskov
205.452.07015 Boehringer Ingelheim Investigational Site
Rostov-on-Don
205.452.07016 Boehringer Ingelheim Investigational Site
Rostov-on-Don
205.452.07039 Boehringer Ingelheim Investigational Site
Ryazan
205.452.07002 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07006 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07011 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07014 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07017 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07018 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07022 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07024 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07025 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07033 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07046 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07052 Boehringer Ingelheim Investigational Site
Saint Petersburg
205.452.07034 Boehringer Ingelheim Investigational Site
Samara
205.452.07047 Boehringer Ingelheim Investigational Site
Saratov
205.452.07032 Boehringer Ingelheim Investigational Site
Tomsk
205.452.07035 Boehringer Ingelheim Investigational Site
Tomsk
205.452.07057 Boehringer Ingelheim Investigational Site
Tomsk
205.452.07019 Boehringer Ingelheim Investigational Site
Velikiy Novgorod
205.452.07044 Boehringer Ingelheim Investigational Site
Yaroslavl
205.452.07031 Boehringer Ingelheim Investigational Site
Yekaterinburg

Other trials in Russia

Canada50 sites

205.452.11030 Boehringer Ingelheim Investigational Site
Burlington, Ontario
205.452.11015 Boehringer Ingelheim Investigational Site
Calgary, Alberta
205.452.11032 Boehringer Ingelheim Investigational Site
Calgary, Alberta
205.452.11042 Boehringer Ingelheim Investigational Site
Corunna, Ontario
205.452.11049 Boehringer Ingelheim Investigational Site
Courtice, Ontario
205.452.11004 Boehringer Ingelheim Investigational Site
Downsview, Ontario
205.452.11028 Boehringer Ingelheim Investigational Site
Edmonton, Alberta
205.452.11037 Boehringer Ingelheim Investigational Site
Edmonton, Alberta
205.452.11045 Boehringer Ingelheim Investigational Site
Edmonton, Alberta
205.452.11047 Boehringer Ingelheim Investigational Site
Edmonton, Alberta
205.452.11044 Boehringer Ingelheim Investigational Site
Grand Falls-Windsor, Newfoundland and Labrador
205.452.11007 Boehringer Ingelheim Investigational Site
Greenfield Park, Quebec
205.452.11009 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
205.452.11029 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
205.452.11050 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
205.452.11048 Boehringer Ingelheim Investigational Site
Kelowna, British Columbia
205.452.11040 Boehringer Ingelheim Investigational Site
Kingston, Ontario
205.452.11005 Boehringer Ingelheim Investigational Site
La Malbaie, Quebec
205.452.11035 Boehringer Ingelheim Investigational Site
London, Ontario
205.452.11006 Boehringer Ingelheim Investigational Site
Longueuil, Quebec
205.452.11051 Boehringer Ingelheim Investigational Site
Maple Ridge, British Columbia
205.452.11001 Boehringer Ingelheim Investigational Site
Mississauga, Ontario
205.452.11054 Boehringer Ingelheim Investigational Site
Mississauga, Ontario
205.452.11033 Boehringer Ingelheim Investigational Site
Moncton, New Brunswick
205.452.11043 Boehringer Ingelheim Investigational Site
Montreal, Quebec
205.452.11053 Boehringer Ingelheim Investigational Site
Mount Pearl, Newfoundland and Labrador
205.452.11022 Boehringer Ingelheim Investigational Site
Newmarket, Ontario
205.452.11024 Boehringer Ingelheim Investigational Site
Ottawa, Ontario
205.452.11013 Boehringer Ingelheim Investigational Site
Point Claire, Quebec
205.452.11031 Boehringer Ingelheim Investigational Site
Québec, Quebec
205.452.11027 Boehringer Ingelheim Investigational Site
Richmond Hill, Ontario
205.452.11010 Boehringer Ingelheim Investigational Site
Saint John, New Brunswick
205.452.11020 Boehringer Ingelheim Investigational Site
Saint-Lambert, Quebec
205.452.11041 Boehringer Ingelheim Investigational Site
Sarnia, Ontario
205.452.11003 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan
205.452.11011 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan
205.452.11036 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan
205.452.11039 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan
205.452.11018 Boehringer Ingelheim Investigational Site
Sherbrooke, Quebec
205.452.11002 Boehringer Ingelheim Investigational Site
Spruce Grove, Alberta
205.452.11017 Boehringer Ingelheim Investigational Site
St. John's, Newfoundland and Labrador
205.452.11021 Boehringer Ingelheim Investigational Site
St. John's, Newfoundland and Labrador
205.452.11019 Boehringer Ingelheim Investigational Site
Toronto, Ontario
205.452.11034 Boehringer Ingelheim Investigational Site
Toronto, Ontario
205.452.11052 Boehringer Ingelheim Investigational Site
Toronto, Ontario
205.452.11026 Boehringer Ingelheim Investigational Site
Trois-Rivières, Quebec
205.452.11014 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia
205.452.11016 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia
205.452.11012 Boehringer Ingelheim Investigational Site
Windsor, Ontario
205.452.11025 Boehringer Ingelheim Investigational Site
Winnipeg, Manitoba

Other trials in Canada

Poland47 sites

205.452.48031 Boehringer Ingelheim Investigational Site
Babice
205.452.48003 Boehringer Ingelheim Investigational Site
Bialystok
205.452.48011 Boehringer Ingelheim Investigational Site
Bialystok
205.452.48014 Boehringer Ingelheim Investigational Site
Bydgoszcz
205.452.48008 Boehringer Ingelheim Investigational Site
Chęciny
205.452.48016 Boehringer Ingelheim Investigational Site
Gdansk
205.452.48019 Boehringer Ingelheim Investigational Site
Gdynia
205.452.48037 Boehringer Ingelheim Investigational Site
Gorzow Wlkp
205.452.48015 Boehringer Ingelheim Investigational Site
Iława
205.452.48033 Boehringer Ingelheim Investigational Site
Katowice
205.452.48039 Boehringer Ingelheim Investigational Site
Katowice
205.452.48044 Boehringer Ingelheim Investigational Site
Katowice
205.452.48009 Boehringer Ingelheim Investigational Site
Krakow
205.452.48021 Boehringer Ingelheim Investigational Site
Krakow
205.452.48029 Boehringer Ingelheim Investigational Site
Krakow
205.452.48030 Boehringer Ingelheim Investigational Site
Krakow
205.452.48048 Boehringer Ingelheim Investigational Site
Krakow
205.452.48043 Boehringer Ingelheim Investigational Site
Libiąż
205.452.48002 Boehringer Ingelheim Investigational Site
Lodz
205.452.48051 Boehringer Ingelheim Investigational Site
Lodz
205.452.48056 Boehringer Ingelheim Investigational Site
Lodz
205.452.48059 Boehringer Ingelheim Investigational Site
Lodz
205.452.48018 Boehringer Ingelheim Investigational Site
Olsztyn
205.452.48025 Boehringer Ingelheim Investigational Site
Ostrow Wielkopolska
205.452.48012 Boehringer Ingelheim Investigational Site
Piaseczno
205.452.48040 Boehringer Ingelheim Investigational Site
Piaseczno
205.452.48026 Boehringer Ingelheim Investigational Site
Poznan
205.452.48027 Boehringer Ingelheim Investigational Site
Poznan
205.452.48058 Boehringer Ingelheim Investigational Site
Poznan
205.452.48060 Boehringer Ingelheim Investigational Site
Rokietnica
205.452.48001 Boehringer Ingelheim Investigational Site
Skierniewice
205.452.48032 Boehringer Ingelheim Investigational Site
Sławków
205.452.48036 Boehringer Ingelheim Investigational Site
Szczecin
205.452.48045 Boehringer Ingelheim Investigational Site
Tarnów
205.452.48057 Boehringer Ingelheim Investigational Site
Tczew
205.452.48004 Boehringer Ingelheim Investigational Site
Torun
205.452.48007 Boehringer Ingelheim Investigational Site
Tranow
205.452.48053 Boehringer Ingelheim Investigational Site
Turek
205.452.48034 Boehringer Ingelheim Investigational Site
Warsaw
205.452.48042 Boehringer Ingelheim Investigational Site
Warsaw
205.452.48049 Boehringer Ingelheim Investigational Site
Warsaw
205.452.48017 Boehringer Ingelheim Investigational Site
Wołomin
205.452.48006 Boehringer Ingelheim Investigational Site
Wroclaw
205.452.48028 Boehringer Ingelheim Investigational Site
Wroclaw
205.452.48035 Boehringer Ingelheim Investigational Site
Wroclaw
205.452.48038 Boehringer Ingelheim Investigational Site
Wroclaw
205.452.48022 Boehringer Ingelheim Investigational Site
Zakopane

Other trials in Poland

China36 sites

205.452.86009 Boehringer Ingelheim Investigational Site
Beijing
205.452.86010 Boehringer Ingelheim Investigational Site
Beijing
205.452.86011 Boehringer Ingelheim Investigational Site
Beijing
205.452.86012 Boehringer Ingelheim Investigational Site
Beijing
205.452.86038 Boehringer Ingelheim Investigational Site
Beijing
205.452.86026 Boehringer Ingelheim Investigational Site
Changchun
205.452.86024 Boehringer Ingelheim Investigational Site
Changsha
205.452.86025 Boehringer Ingelheim Investigational Site
Changsha
205.452.86021 Boehringer Ingelheim Investigational Site
Chengdu
205.452.86032 Boehringer Ingelheim Investigational Site
Chengdu
205.452.86034 Boehringer Ingelheim Investigational Site
Chongqing
205.452.86035 Boehringer Ingelheim Investigational Site
Chongqing
205.452.86036 Boehringer Ingelheim Investigational Site
Chongqing
205.452.86020 Boehringer Ingelheim Investigational Site
Foshan
205.452.86001 Boehringer Ingelheim Investigational Site
Guangzhou
205.452.86004 Boehringer Ingelheim Investigational Site
Guangzhou
205.452.86005 Boehringer Ingelheim Investigational Site
Guangzhou
205.452.86019 Boehringer Ingelheim Investigational Site
Guangzhou
205.452.86028 Boehringer Ingelheim Investigational Site
Guangzhou
205.452.86030 Boehringer Ingelheim Investigational Site
Haikou
205.452.86007 Boehringer Ingelheim Investigational Site
Hangzhou
205.452.86008 Boehringer Ingelheim Investigational Site
Hangzhou
205.452.86037 Boehringer Ingelheim Investigational Site
Nanchang
205.452.86022 Boehringer Ingelheim Investigational Site
Nanjing
205.452.86029 Boehringer Ingelheim Investigational Site
Nanning
205.452.86027 Boehringer Ingelheim Investigational Site
Qingdao
205.452.86002 Boehringer Ingelheim Investigational Site
Shanghai
205.452.86003 Boehringer Ingelheim Investigational Site
Shanghai
205.452.86018 Boehringer Ingelheim Investigational Site
Shanghai
205.452.86014 Boehringer Ingelheim Investigational Site
Shenyang
205.452.86015 Boehringer Ingelheim Investigational Site
Shenyang
205.452.86006 Boehringer Ingelheim Investigational Site
Suzhou
205.452.86033 Boehringer Ingelheim Investigational Site
Tianjin
205.452.86031 Boehringer Ingelheim Investigational Site
Wuhan
205.452.86016 Boehringer Ingelheim Investigational Site
Xi'an
205.452.86017 Boehringer Ingelheim Investigational Site
Xi'an

Other trials in China

Hungary30 sites

205.452.36005 Boehringer Ingelheim Investigational Site
Baja
205.452.36004 Boehringer Ingelheim Investigational Site
Budapest
205.452.36016 Boehringer Ingelheim Investigational Site
Budapest
205.452.36030 Boehringer Ingelheim Investigational Site
Budapest
205.452.36007 Boehringer Ingelheim Investigational Site
Debrecen
205.452.36013 Boehringer Ingelheim Investigational Site
Debrecen
205.452.36015 Boehringer Ingelheim Investigational Site
Debrecen
205.452.36029 Boehringer Ingelheim Investigational Site
Deszk
205.452.36026 Boehringer Ingelheim Investigational Site
Dombóvár
205.452.36003 Boehringer Ingelheim Investigational Site
Érd
205.452.36008 Boehringer Ingelheim Investigational Site
Farkasgyepü
205.452.36020 Boehringer Ingelheim Investigational Site
Győr
205.452.36012 Boehringer Ingelheim Investigational Site
Hajduböszörmeny
205.452.36023 Boehringer Ingelheim Investigational Site
Hódmezővásárhely
205.452.36010 Boehringer Ingelheim Investigational Site
Kaposvár
205.452.36018 Boehringer Ingelheim Investigational Site
Kapuvár
205.452.36002 Boehringer Ingelheim Investigational Site
Kecskemét
205.452.36001 Boehringer Ingelheim Investigational Site
Makó
205.452.36006 Boehringer Ingelheim Investigational Site
Mohács
205.452.36022 Boehringer Ingelheim Investigational Site
Mosonmagyaróvár
205.452.36027 Boehringer Ingelheim Investigational Site
Nagykanizsa
205.452.36014 Boehringer Ingelheim Investigational Site
Nyíregyháza
205.452.36009 Boehringer Ingelheim Investigational Site
Pécs
205.452.36011 Boehringer Ingelheim Investigational Site
Pécs
205.452.36028 Boehringer Ingelheim Investigational Site
Siófok
205.452.36021 Boehringer Ingelheim Investigational Site
Szarvas
205.452.36017 Boehringer Ingelheim Investigational Site
Szeged
205.452.36024 Boehringer Ingelheim Investigational Site
Tatabánya
205.452.36019 Boehringer Ingelheim Investigational Site
Törökbálint
205.452.36025 Boehringer Ingelheim Investigational Site
Törökbálint

Other trials in Hungary

Ukraine26 sites

205.452.38028 Boehringer Ingelheim Investigational Site
Crimea
205.452.38024 Boehringer Ingelheim Investigational Site
Dnipropetrovks
205.452.38022 Boehringer Ingelheim Investigational Site
Dnipropetrovsk
205.452.38034 Boehringer Ingelheim Investigational Site
Dnyepropyetrovsk
205.452.38002 Boehringer Ingelheim Investigational Site
Donetsk
205.452.38020 Boehringer Ingelheim Investigational Site
Donetsk
205.452.38011 Boehringer Ingelheim Investigational Site
Ivano-Frankivsk
205.452.38001 Boehringer Ingelheim Investigational Site
Kharkiv
205.452.38004 Boehringer Ingelheim Investigational Site
Kharkiv
205.452.38005 Boehringer Ingelheim Investigational Site
Kharkiv
205.452.38006 Boehringer Ingelheim Investigational Site
Kharkiv
205.452.38008 Boehringer Ingelheim Investigational Site
Kharkiv
205.452.38018 Boehringer Ingelheim Investigational Site
Kharkiv
205.452.38003 Boehringer Ingelheim Investigational Site
Kiev
205.452.38010 Boehringer Ingelheim Investigational Site
Kiev
205.452.38012 Boehringer Ingelheim Investigational Site
Kiev
205.452.38013 Boehringer Ingelheim Investigational Site
Kiev
205.452.38015 Boehringer Ingelheim Investigational Site
Kiev
205.452.38032 Boehringer Ingelheim Investigational Site
Kiev
205.452.38026 Boehringer Ingelheim Investigational Site
Nikolayev
205.452.38023 Boehringer Ingelheim Investigational Site
Odesa
205.452.38027 Boehringer Ingelheim Investigational Site
Odesa
205.452.38031 Boehringer Ingelheim Investigational Site
Odesa
205.452.38017 Boehringer Ingelheim Investigational Site
Simferopol
205.452.38019 Boehringer Ingelheim Investigational Site
Vinnytsia
205.452.38030 Boehringer Ingelheim Investigational Site
Zaporizhzhya

Other trials in Ukraine

Italy25 sites

205.452.39003 Boehringer Ingelheim Investigational Site
Arenzano (ge)
205.452.39019 Boehringer Ingelheim Investigational Site
Ascoli Piceno
205.452.39016 Boehringer Ingelheim Investigational Site
Avellino
205.452.39007 Boehringer Ingelheim Investigational Site
Benevento
205.452.39024 Boehringer Ingelheim Investigational Site
Brescia
205.452.39029 Boehringer Ingelheim Investigational Site
Busto Arsizio (va)
205.452.39011 Boehringer Ingelheim Investigational Site
Cagliari
205.452.39013 Boehringer Ingelheim Investigational Site
Cagliari
205.452.39020 Boehringer Ingelheim Investigational Site
Cagliari
205.452.39015 Boehringer Ingelheim Investigational Site
Catanzaro
205.452.39006 Boehringer Ingelheim Investigational Site
Chieti Scalo
205.452.39001 Boehringer Ingelheim Investigational Site
Florence
205.452.39021 Boehringer Ingelheim Investigational Site
Monza
205.452.39014 Boehringer Ingelheim Investigational Site
Naples
205.452.39012 Boehringer Ingelheim Investigational Site
Orbassano (to)
205.452.39026 Boehringer Ingelheim Investigational Site
Orbassano (to)
205.452.39010 Boehringer Ingelheim Investigational Site
Palermo
205.452.39005 Boehringer Ingelheim Investigational Site
Parma
205.452.39009 Boehringer Ingelheim Investigational Site
Perugia
205.452.39002 Boehringer Ingelheim Investigational Site
Prato
205.452.39030 Boehringer Ingelheim Investigational Site
Reggio Emilia
205.452.39004 Boehringer Ingelheim Investigational Site
Roma
205.452.39017 Boehringer Ingelheim Investigational Site
Roma
205.452.39027 Boehringer Ingelheim Investigational Site
Roma
205.452.39023 Boehringer Ingelheim Investigational Site
Treviso

Other trials in Italy

Spain24 sites

205.452.34018 Boehringer Ingelheim Investigational Site
Badajoz
205.452.34021 Boehringer Ingelheim Investigational Site
Badalona (Barcelona)
205.452.34010 Boehringer Ingelheim Investigational Site
Barcelona
205.452.34025 Boehringer Ingelheim Investigational Site
Barcelona
205.452.34015 Boehringer Ingelheim Investigational Site
Cáceres
205.452.34027 Boehringer Ingelheim Investigational Site
Centelles
205.452.34016 Boehringer Ingelheim Investigational Site
Elda
205.452.34008 Boehringer Ingelheim Investigational Site
L'Hospitalet de Llobregat
205.452.34026 Boehringer Ingelheim Investigational Site
Lugo
205.452.34011 Boehringer Ingelheim Investigational Site
Madrid
205.452.34019 Boehringer Ingelheim Investigational Site
Madrid
205.452.34020 Boehringer Ingelheim Investigational Site
Málaga
205.452.34002 Boehringer Ingelheim Investigational Site
Mérida
205.452.34017 Boehringer Ingelheim Investigational Site
Plasencia
205.452.34001 Boehringer Ingelheim Investigational Site
Pozuelo de Alarcón
205.452.34024 Boehringer Ingelheim Investigational Site
Sant Joan d'Alacant
205.452.34003 Boehringer Ingelheim Investigational Site
Santander
205.452.34005 Boehringer Ingelheim Investigational Site
Terrassa (Barcelona)
205.452.34007 Boehringer Ingelheim Investigational Site
Torrevieja
205.452.34012 Boehringer Ingelheim Investigational Site
Valencia
205.452.34013 Boehringer Ingelheim Investigational Site
Valladolid
205.452.34009 Boehringer Ingelheim Investigational Site
Vic (Barcelona)
205.452.34023 Boehringer Ingelheim Investigational Site
Vilanova i la Geltrú
205.452.34004 Boehringer Ingelheim Investigational Site
Zaragoza

Other trials in Spain

South Korea20 sites

205.452.82008 Boehringer Ingelheim Investigational Site
Bucheon-si
205.452.82002 Boehringer Ingelheim Investigational Site
Busan
205.452.82012 Boehringer Ingelheim Investigational Site
Busan
205.452.82010 Boehringer Ingelheim Investigational Site
Daegu
205.452.82016 Boehringer Ingelheim Investigational Site
Daejoen
205.452.82009 Boehringer Ingelheim Investigational Site
Gangwon-Do
205.452.82017 Boehringer Ingelheim Investigational Site
Goyang
205.452.82004 Boehringer Ingelheim Investigational Site
Gwangju
205.452.82005 Boehringer Ingelheim Investigational Site
Incheon
205.452.82020 Boehringer Ingelheim Investigational Site
Jeonju
205.452.82001 Boehringer Ingelheim Investigational Site
Seoul
205.452.82003 Boehringer Ingelheim Investigational Site
Seoul
205.452.82006 Boehringer Ingelheim Investigational Site
Seoul
205.452.82007 Boehringer Ingelheim Investigational Site
Seoul
205.452.82011 Boehringer Ingelheim Investigational Site
Seoul
205.452.82013 Boehringer Ingelheim Investigational Site
Seoul
205.452.82014 Boehringer Ingelheim Investigational Site
Seoul
205.452.82015 Boehringer Ingelheim Investigational Site
Seoul
205.452.82018 Boehringer Ingelheim Investigational Site
Seoul
205.452.82019 Boehringer Ingelheim Investigational Site
Uijeongbu-si

Other trials in South Korea

Argentina16 sites

205.452.54003 Boehringer Ingelheim Investigational Site
Capital Federal
205.452.54011 Boehringer Ingelheim Investigational Site
Capital Federal
205.452.54013 Boehringer Ingelheim Investigational Site
Capital Federal
205.452.54027 Boehringer Ingelheim Investigational Site
Capital Federal
205.452.54029 Boehringer Ingelheim Investigational Site
Capital Federal
205.452.54031 Boehringer Ingelheim Investigational Site
Capital Federal
205.452.54007 Boehringer Ingelheim Investigational Site
Mar del Plata
205.452.54015 Boehringer Ingelheim Investigational Site
Mar del Plata
205.452.54001 Boehringer Ingelheim Investigational Site
Mendoza
205.452.54019 Boehringer Ingelheim Investigational Site
Monte Grande
205.452.54005 Boehringer Ingelheim Investigational Site
Quilmes
205.452.54009 Boehringer Ingelheim Investigational Site
Rosario
205.452.54021 Boehringer Ingelheim Investigational Site
Rosario
205.452.54025 Boehringer Ingelheim Investigational Site
San Juan Bautista
205.452.54017 Boehringer Ingelheim Investigational Site
San Miguel de Tucumán
205.452.54023 Boehringer Ingelheim Investigational Site
San Miguel de Tucumán

Other trials in Argentina

Turkey (Türkiye)16 sites

205.452.90001 Boehringer Ingelheim Investigational Site
Adana
205.452.90008 Boehringer Ingelheim Investigational Site
Ankara
205.452.90013 Boehringer Ingelheim Investigational Site
Ankara
205.452.90005 Boehringer Ingelheim Investigational Site
Antalya
205.452.90018 Boehringer Ingelheim Investigational Site
Aydin
205.452.90003 Boehringer Ingelheim Investigational Site
Bolu
205.452.90006 Boehringer Ingelheim Investigational Site
Edirne
205.452.90010 Boehringer Ingelheim Investigational Site
Erzurum
205.452.90019 Boehringer Ingelheim Investigational Site
Hatay
205.452.90017 Boehringer Ingelheim Investigational Site
Istanbul
205.452.90020 Boehringer Ingelheim Investigational Site
Istanbul
205.452.90021 Boehringer Ingelheim Investigational Site
Istanbul
205.452.90015 Boehringer Ingelheim Investigational Site
Izmir
205.452.90016 Boehringer Ingelheim Investigational Site
Izmir
205.452.90022 Boehringer Ingelheim Investigational Site
Izmir
205.452.90007 Boehringer Ingelheim Investigational Site
Malatya

Other trials in Turkey (Türkiye)

Denmark15 sites

205.452.45002 Boehringer Ingelheim Investigational Site
Aalborg
205.452.45003 Boehringer Ingelheim Investigational Site
Aarhus C
205.452.45006 Boehringer Ingelheim Investigational Site
Birkerød
205.452.45001 Boehringer Ingelheim Investigational Site
København NV
205.452.45005 Boehringer Ingelheim Investigational Site
København S
205.452.45013 Boehringer Ingelheim Investigational Site
Kolding
205.452.45012 Boehringer Ingelheim Investigational Site
Odense C
205.452.45009 Boehringer Ingelheim Investigational Site
Rødovre Municipality
205.452.45010 Boehringer Ingelheim Investigational Site
Rødovre Municipality
205.452.45016 Boehringer Ingelheim Investigational Site
Roskilde
205.452.45004 Boehringer Ingelheim Investigational Site
Silkeborg
205.452.45014 Boehringer Ingelheim Investigational Site
Skive
205.452.45011 Boehringer Ingelheim Investigational Site
Sønderborg
205.452.45007 Boehringer Ingelheim Investigational Site
Værløse
205.452.45015 Boehringer Ingelheim Investigational Site
Viby J

Other trials in Denmark

India15 sites

205.452.91017 Boehringer Ingelheim Investigational Site
Ahmedabad
205.452.91018 Boehringer Ingelheim Investigational Site
Chennai
205.452.91001 Boehringer Ingelheim Investigational Site
Coimbatore
205.452.91002 Boehringer Ingelheim Investigational Site
Coimbatore
205.452.91014 Boehringer Ingelheim Investigational Site
Dadar(East)
205.452.91005 Boehringer Ingelheim Investigational Site
Hyderabad
205.452.91009 Boehringer Ingelheim Investigational Site
Hyderabad
205.452.91004 Boehringer Ingelheim Investigational Site
Jaipur
205.452.91007 Boehringer Ingelheim Investigational Site
Jaipur
205.452.91015 Boehringer Ingelheim Investigational Site
Jaipur
205.452.91016 Boehringer Ingelheim Investigational Site
Jaipur
205.452.91008 Boehringer Ingelheim Investigational Site
Karnataka
205.452.91006 Boehringer Ingelheim Investigational Site
Maharashtra
205.452.91003 Boehringer Ingelheim Investigational Site
Maharastra
205.452.91011 Boehringer Ingelheim Investigational Site
Punjab

Other trials in India

South Africa14 sites

205.452.27002 Boehringer Ingelheim Investigational Site
Bellville
205.452.27010 Boehringer Ingelheim Investigational Site
Bloemfontein
205.452.27001 Boehringer Ingelheim Investigational Site
Cape Town
205.452.27004 Boehringer Ingelheim Investigational Site
Cape Town
205.452.27008 Boehringer Ingelheim Investigational Site
Cape Town
205.452.27011 Boehringer Ingelheim Investigational Site
Cape Town
205.452.27012 Boehringer Ingelheim Investigational Site
Cape Town
205.452.27006 Boehringer Ingelheim Investigational Site
Centurion
205.452.27003 Boehringer Ingelheim Investigational Site
Durban
205.452.27013 Boehringer Ingelheim Investigational Site
eManzimtoti
205.452.27014 Boehringer Ingelheim Investigational Site
Johannesburg
205.452.27005 Boehringer Ingelheim Investigational Site
Pretoria
205.452.27009 Boehringer Ingelheim Investigational Site
Pretoria
205.452.27007 Boehringer Ingelheim Investigational Site
Somerset West

Other trials in South Africa

Taiwan14 sites

205.452.88607 Boehringer Ingelheim Investigational Site
Changhua
205.452.88614 Boehringer Ingelheim Investigational Site
Chiayi City
205.452.88608 Boehringer Ingelheim Investigational Site
Kaohsiung City
205.452.88609 Boehringer Ingelheim Investigational Site
Kaohsiung City
205.452.88611 Boehringer Ingelheim Investigational Site
Kaohsiung City
205.452.88604 Boehringer Ingelheim Investigational Site
New Taipei City
205.452.88605 Boehringer Ingelheim Investigational Site
Taichung
205.452.88606 Boehringer Ingelheim Investigational Site
Taichung
205.452.88612 Boehringer Ingelheim Investigational Site
Taichung
205.452.88610 Boehringer Ingelheim Investigational Site
Tainan
205.452.88602 Boehringer Ingelheim Investigational Site
Taipei
205.452.88603 Boehringer Ingelheim Investigational Site
Taipei
205.452.88613 Boehringer Ingelheim Investigational Site
Taipei
205.452.88601 Boehringer Ingelheim Investigational Site
Taoyuan County

Other trials in Taiwan

Slovakia13 sites

205.452.42103 Boehringer Ingelheim Investigational Site
Bardejov
205.452.42107 Boehringer Ingelheim Investigational Site
Bratislava
205.452.42102 Boehringer Ingelheim Investigational Site
Humenné
205.452.42105 Boehringer Ingelheim Investigational Site
Košice
205.452.42111 Boehringer Ingelheim Investigational Site
Košice
205.452.42113 Boehringer Ingelheim Investigational Site
Košice
205.452.42108 Boehringer Ingelheim Investigational Site
Levice
205.452.42109 Boehringer Ingelheim Investigational Site
Martin
205.452.42112 Boehringer Ingelheim Investigational Site
Poprad
205.452.42101 Boehringer Ingelheim Investigational Site
Prešov
205.452.42104 Boehringer Ingelheim Investigational Site
Rimavská Sobota
205.452.42106 Boehringer Ingelheim Investigational Site
Spišská Nová Ves
205.452.42110 Boehringer Ingelheim Investigational Site
Štúrovo

Other trials in Slovakia

Sweden13 sites

205.452.46005 Boehringer Ingelheim Investigational Site
Brämhult
205.452.46014 Boehringer Ingelheim Investigational Site
Eksjö
205.452.46013 Boehringer Ingelheim Investigational Site
Gothenburg
205.452.46012 Boehringer Ingelheim Investigational Site
Gullspång
205.452.46001 Boehringer Ingelheim Investigational Site
Höllviken
205.452.46008 Boehringer Ingelheim Investigational Site
Järfälla
205.452.46009 Boehringer Ingelheim Investigational Site
Kil
205.452.46007 Boehringer Ingelheim Investigational Site
Lidingö
205.452.46003 Boehringer Ingelheim Investigational Site
Luleå
205.452.46006 Boehringer Ingelheim Investigational Site
Örebro
205.452.46010 Boehringer Ingelheim Investigational Site
Sigtuna
205.452.46002 Boehringer Ingelheim Investigational Site
Solna
205.452.46011 Boehringer Ingelheim Investigational Site
Uddevalla

Other trials in Sweden

Switzerland13 sites

205.452.41003 Boehringer Ingelheim Investigational Site
Ascona
205.452.41004 Boehringer Ingelheim Investigational Site
Basel
205.452.41016 Boehringer Ingelheim Investigational Site
Bern
205.452.41012 Boehringer Ingelheim Investigational Site
Glarus
205.452.41001 Boehringer Ingelheim Investigational Site
Gossau
205.452.41015 Boehringer Ingelheim Investigational Site
Liestal
205.452.41010 Boehringer Ingelheim Investigational Site
Locarno
205.452.41011 Boehringer Ingelheim Investigational Site
Lugano
205.452.41002 Boehringer Ingelheim Investigational Site
Sankt Gallen
205.452.41009 Boehringer Ingelheim Investigational Site
Sankt Gallen
205.452.41007 Boehringer Ingelheim Investigational Site
Spiez
205.452.41013 Boehringer Ingelheim Investigational Site
Zurich
205.452.41014 Boehringer Ingelheim Investigational Site
Zurich

Other trials in Switzerland

Bulgaria12 sites

205.452.35909 Boehringer Ingelheim Investigational Site
Plovdiv
205.452.35910 Boehringer Ingelheim Investigational Site
Plovdiv
205.452.35901 Boehringer Ingelheim Investigational Site
Sofia
205.452.35902 Boehringer Ingelheim Investigational Site
Sofia
205.452.35903 Boehringer Ingelheim Investigational Site
Sofia
205.452.35904 Boehringer Ingelheim Investigational Site
Sofia
205.452.35905 Boehringer Ingelheim Investigational Site
Sofia
205.452.35908 Boehringer Ingelheim Investigational Site
Sofia
205.452.35914 Boehringer Ingelheim Investigational Site
Sofia
205.452.35915 Boehringer Ingelheim Investigational Site
Sofia
205.452.35912 Boehringer Ingelheim Investigational Site
Stara Zagora
205.452.35906 Boehringer Ingelheim Investigational Site
Veliko Tarnovo

Other trials in Bulgaria

Croatia12 sites

205.452.38512 Boehringer Ingelheim Investigational Site
Čakovec
205.452.38508 Boehringer Ingelheim Investigational Site
Dubrovnik
205.452.38510 Boehringer Ingelheim Investigational Site
Osijek
205.452.38501 Boehringer Ingelheim Investigational Site
Rijeka
205.452.38506 Boehringer Ingelheim Investigational Site
Sisak
205.452.38502 Boehringer Ingelheim Investigational Site
Split
205.452.38503 Boehringer Ingelheim Investigational Site
Split
205.452.38504 Boehringer Ingelheim Investigational Site
Zagreb
205.452.38505 Boehringer Ingelheim Investigational Site
Zagreb
205.452.38507 Boehringer Ingelheim Investigational Site
Zagreb
205.452.38509 Boehringer Ingelheim Investigational Site
Zagreb
205.452.38511 Boehringer Ingelheim Investigational Site
Zagreb

Other trials in Croatia

Greece12 sites

205.452.30002 Boehringer Ingelheim Investigational Site
Athens
205.452.30003 Boehringer Ingelheim Investigational Site
Athens
205.452.30008 Boehringer Ingelheim Investigational Site
Athens
205.452.30001 Boehringer Ingelheim Investigational Site
Heraklion
205.452.30007 Boehringer Ingelheim Investigational Site
Kalamaria
205.452.30010 Boehringer Ingelheim Investigational Site
Kavala
205.452.30012 Boehringer Ingelheim Investigational Site
Lamia
205.452.30005 Boehringer Ingelheim Investigational Site
Nafplion
205.452.30011 Boehringer Ingelheim Investigational Site
Rethymno
205.452.30006 Boehringer Ingelheim Investigational Site
Serres
205.452.30004 Boehringer Ingelheim Investigational Site
Thessaloniki
205.452.30009 Boehringer Ingelheim Investigational Site
Thessaloniki

Other trials in Greece

Norway12 sites

205.452.47008 Boehringer Ingelheim Investigational Site
Drammen
205.452.47009 Boehringer Ingelheim Investigational Site
Fredrikstad
205.452.47001 Boehringer Ingelheim Investigational Site
Hønefoss
205.452.47010 Boehringer Ingelheim Investigational Site
Kløfta
205.452.47007 Boehringer Ingelheim Investigational Site
Kolbjørnsvik
205.452.47005 Boehringer Ingelheim Investigational Site
Løvenstad
205.452.47002 Boehringer Ingelheim Investigational Site
Oslo
205.452.47003 Boehringer Ingelheim Investigational Site
Oslo
205.452.47011 Boehringer Ingelheim Investigational Site
Oslo
205.452.47012 Boehringer Ingelheim Investigational Site
Sandvika
205.452.47004 Boehringer Ingelheim Investigational Site
Svelvik
205.452.47006 Boehringer Ingelheim Investigational Site
Trollåsen

Other trials in Norway

Brazil11 sites

205.452.55005 Boehringer Ingelheim Investigational Site
Florianópolis
205.452.55010 Boehringer Ingelheim Investigational Site
Passo Fundo - RS
205.452.55001 Boehringer Ingelheim Investigational Site
Porto Alegre
205.452.55002 Boehringer Ingelheim Investigational Site
Porto Alegre
205.452.55003 Boehringer Ingelheim Investigational Site
Recife
205.452.55004 Boehringer Ingelheim Investigational Site
Rio de Janeiro
205.452.55011 Boehringer Ingelheim Investigational Site
Rio de Janeiro
205.452.55008 Boehringer Ingelheim Investigational Site
Sao Pablo
205.452.55006 Boehringer Ingelheim Investigational Site
São Paulo
205.452.55007 Boehringer Ingelheim Investigational Site
São Paulo
205.452.55009 Boehringer Ingelheim Investigational Site
São Paulo

Other trials in Brazil

Romania11 sites

205.452.40008 Boehringer Ingelheim Investigational Site
Brasov
205.452.40012 Boehringer Ingelheim Investigational Site
Brasov
205.452.40001 Boehringer Ingelheim Investigational Site
Bucharest
205.452.40002 Boehringer Ingelheim Investigational Site
Bucharest
205.452.40003 Boehringer Ingelheim Investigational Site
Bucharest
205.452.40004 Boehringer Ingelheim Investigational Site
Bucharest
205.452.40007 Boehringer Ingelheim Investigational Site
Bucharest
205.452.40009 Boehringer Ingelheim Investigational Site
Bucharest
205.452.40013 Boehringer Ingelheim Investigational Site
Bucharest
205.452.40011 Boehringer Ingelheim Investigational Site
Constanța
205.452.40006 Boehringer Ingelheim Investigational Site
Craiova

Other trials in Romania

Latvia10 sites

205.452.37106 Boehringer Ingelheim Investigational Site
Daugavpils
205.452.37107 Boehringer Ingelheim Investigational Site
Daugavpils
205.452.37108 Boehringer Ingelheim Investigational Site
Daugavpils
205.452.37102 Boehringer Ingelheim Investigational Site
Krāslava
205.452.37104 Boehringer Ingelheim Investigational Site
Riga
205.452.37105 Boehringer Ingelheim Investigational Site
Riga
205.452.37109 Boehringer Ingelheim Investigational Site
Riga
205.452.37110 Boehringer Ingelheim Investigational Site
Riga
205.452.37101 Boehringer Ingelheim Investigational Site
Talsi
205.452.37103 Boehringer Ingelheim Investigational Site
Valmiera

Other trials in Latvia

Tunisia10 sites

205.452.21603 Boehringer Ingelheim Investigational Site
Aryanah
205.452.21605 Boehringer Ingelheim Investigational Site
Aryanah
205.452.21606 Boehringer Ingelheim Investigational Site
Aryanah
205.452.21607 Boehringer Ingelheim Investigational Site
Aryanah
205.452.21610 Boehringer Ingelheim Investigational Site
Mahdia
205.452.21609 Boehringer Ingelheim Investigational Site
Monastir
205.452.21608 Boehringer Ingelheim Investigational Site
Nabeul
205.452.21601 Boehringer Ingelheim Investigational Site
Tunis
205.452.21602 Boehringer Ingelheim Investigational Site
Tunis
205.452.21604 Boehringer Ingelheim Investigational Site
Tunis

Other trials in Tunisia

United Kingdom10 sites

205.452.44010 Boehringer Ingelheim Investigational Site
Atherstone
205.452.44008 Boehringer Ingelheim Investigational Site
Burbage
205.452.44004 Boehringer Ingelheim Investigational Site
Chertsey
205.452.44002 Boehringer Ingelheim Investigational Site
Chesterfield
205.452.44003 Boehringer Ingelheim Investigational Site
Coventry
205.452.44001 Boehringer Ingelheim Investigational Site
Exeter
205.452.44007 Boehringer Ingelheim Investigational Site
Fowey
205.452.44005 Boehringer Ingelheim Investigational Site
Frome
205.452.44011 Boehringer Ingelheim Investigational Site
Royal Leamington Spa
205.452.44006 Boehringer Ingelheim Investigational Site
Saint Just, Penzance

Other trials in United Kingdom

Belgium9 sites

205.452.32009 Boehringer Ingelheim Investigational Site
Godinne
205.452.32007 Boehringer Ingelheim Investigational Site
Gozée
205.452.32002 Boehringer Ingelheim Investigational Site
Halen
205.452.32001 Boehringer Ingelheim Investigational Site
Leuven
205.452.32006 Boehringer Ingelheim Investigational Site
Linkebeek
205.452.32005 Boehringer Ingelheim Investigational Site
Merksem
205.452.32008 Boehringer Ingelheim Investigational Site
Natoye
205.452.32003 Boehringer Ingelheim Investigational Site
Tessenderlo
205.452.32004 Boehringer Ingelheim Investigational Site
Zichem

Other trials in Belgium

Lithuania9 sites

205.452.37003 Boehringer Ingelheim Investigational Site
Alytus
205.452.37001 Boehringer Ingelheim Investigational Site
Kaunas
205.452.37002 Boehringer Ingelheim Investigational Site
Kaunas
205.452.37005 Boehringer Ingelheim Investigational Site
Klaipėda
205.452.37007 Boehringer Ingelheim Investigational Site
Šiauliai
205.452.37011 Boehringer Ingelheim Investigational Site
Utena
205.452.37004 Boehringer Ingelheim Investigational Site
Vilnius
205.452.37008 Boehringer Ingelheim Investigational Site
Vilnius
205.452.37010 Boehringer Ingelheim Investigational Site
Vilnius

Other trials in Lithuania

Netherlands9 sites

205.452.31001 Boehringer Ingelheim Investigational Site
Almere Stad
205.452.31008 Boehringer Ingelheim Investigational Site
Andijk
205.452.31002 Boehringer Ingelheim Investigational Site
Beek
205.452.31012 Boehringer Ingelheim Investigational Site
Beek en Donk
205.452.31003 Boehringer Ingelheim Investigational Site
Ermelo
205.452.31010 Boehringer Ingelheim Investigational Site
Hoogwoud
205.452.31011 Boehringer Ingelheim Investigational Site
Nijverdal
205.452.31007 Boehringer Ingelheim Investigational Site
Oude Pekela
205.452.31005 Boehringer Ingelheim Investigational Site
Roelofarendsveen

Other trials in Netherlands

Ireland8 sites

205.452.35307 Boehringer Ingelheim Investigational Site
Co. Cork
205.452.35306 Boehringer Ingelheim Investigational Site
Co. Tipperary
205.452.35305 Boehringer Ingelheim Investigational Site
Co. Wexford
205.452.35301 Boehringer Ingelheim Investigational Site
Dublin
205.452.35302 Boehringer Ingelheim Investigational Site
Dublin
205.452.35303 Boehringer Ingelheim Investigational Site
Limerick
205.452.35308 Boehringer Ingelheim Investigational Site
Limerick
205.452.35304 Boehringer Ingelheim Investigational Site
Offaly

Other trials in Ireland

Israel8 sites

205.452.97207 Boehringer Ingelheim Investigational Site
Ashkelon
205.452.97204 Boehringer Ingelheim Investigational Site
Beersheba
205.452.97208 Boehringer Ingelheim Investigational Site
Haifa
205.452.97202 Boehringer Ingelheim Investigational Site
Jerusalem
205.452.97206 Boehringer Ingelheim Investigational Site
Kfar Saba
205.452.97203 Boehringer Ingelheim Investigational Site
Petah Tikva
205.452.97201 Boehringer Ingelheim Investigational Site
Rehovot
205.452.97205 Boehringer Ingelheim Investigational Site
Tel Aviv

Other trials in Israel

Malaysia8 sites

205.452.60006 Boehringer Ingelheim Investigational Site
Johor Bahru
205.452.60001 Boehringer Ingelheim Investigational Site
Kuala Lumpur
205.452.60002 Boehringer Ingelheim Investigational Site
Kuala Lumpur
205.452.60004 Boehringer Ingelheim Investigational Site
Kuala Lumpur
205.452.60008 Boehringer Ingelheim Investigational Site
Kuala Pahang
205.452.60009 Boehringer Ingelheim Investigational Site
Kuala Selangor
205.452.60005 Boehringer Ingelheim Investigational Site
Sarawak
205.452.60007 Boehringer Ingelheim Investigational Site
Terengganu

Other trials in Malaysia

Philippines8 sites

205.452.63004 Boehringer Ingelheim Investigational Site
Cavite City
205.452.63002 Boehringer Ingelheim Investigational Site
Davao City
205.452.63003 Boehringer Ingelheim Investigational Site
Iloilo City
205.452.63006 Boehringer Ingelheim Investigational Site
Iloilo City
205.452.63001 Boehringer Ingelheim Investigational Site
Manila
205.452.63008 Boehringer Ingelheim Investigational Site
Manila
205.452.63005 Boehringer Ingelheim Investigational Site
Quezon City
205.452.63007 Boehringer Ingelheim Investigational Site
Quezon City

Other trials in Philippines

Portugal8 sites

205.452.35103 Boehringer Ingelheim Investigational Site
Amadora
205.452.35102 Boehringer Ingelheim Investigational Site
Coimbra
205.452.35107 Boehringer Ingelheim Investigational Site
Lisbon
205.452.35108 Boehringer Ingelheim Investigational Site
Lisbon
205.452.35101 Boehringer Ingelheim Investigational Site
Matosinhos Municipality
205.452.35105 Boehringer Ingelheim Investigational Site
Penafiel
205.452.35106 Boehringer Ingelheim Investigational Site
Vila Nova de Gaia
205.452.35104 Boehringer Ingelheim Investigational Site
Viseu

Other trials in Portugal

Finland7 sites

205.452.35806 Boehringer Ingelheim Investigational Site
Ekenäs
205.452.35801 Boehringer Ingelheim Investigational Site
Helsinki
205.452.35804 Boehringer Ingelheim Investigational Site
Lahti
205.452.35808 Boehringer Ingelheim Investigational Site
Pori
205.452.35805 Boehringer Ingelheim Investigational Site
Porvoo
205.452.35802 Boehringer Ingelheim Investigational Site
Tampere
205.452.35803 Boehringer Ingelheim Investigational Site
Turku

Other trials in Finland

Georgia7 sites

205.452.99501 Boehringer Ingelheim Investigational Site
Tbilisi
205.452.99502 Boehringer Ingelheim Investigational Site
Tbilisi
205.452.99503 Boehringer Ingelheim Investigational Site
Tbilisi
205.452.99504 Boehringer Ingelheim Investigational Site
Tbilisi
205.452.99505 Boehringer Ingelheim Investigational Site
Tbilisi
205.452.99506 Boehringer Ingelheim Investigational Site
Tbilisi
205.452.99507 Boehringer Ingelheim Investigational Site
Tbilisi

Other trials in Georgia

Guatemala7 sites

205.452.50205 Boehringer Ingelheim Investigational Site
Guatemala City
205.452.50206 Boehringer Ingelheim Investigational Site
Guatemala City
205.452.50203 Boehringer Ingelheim Investigational Site
Nivel 12
205.452.50201 Boehringer Ingelheim Investigational Site
Nivel Guatemala
205.452.50202 Boehringer Ingelheim Investigational Site
Nivel Guatemala
205.452.50204 Boehringer Ingelheim Investigational Site
Nivel Guatemala
205.452.50207 Boehringer Ingelheim Investigational Site
Quetzaltenango

Other trials in Guatemala

Peru7 sites

205.452.51002 Boehringer Ingelheim Investigational Site
Bellavista
205.452.51003 Boehringer Ingelheim Investigational Site
Cusco
205.452.51004 Boehringer Ingelheim Investigational Site
Jesús Maria
205.452.51007 Boehringer Ingelheim Investigational Site
Jesús María
205.452.51005 Boehringer Ingelheim Investigational Site
Lima
205.452.51001 Boehringer Ingelheim Investigational Site
San Isidro
205.452.51006 Boehringer Ingelheim Investigational Site
San Martín de Porres

Other trials in Peru

Serbia7 sites

205.452.38103 Boehringer Ingelheim Investigational Site
Belgrade
205.452.38104 Boehringer Ingelheim Investigational Site
Belgrade
205.452.38106 Boehringer Ingelheim Investigational Site
Belgrade
205.452.38107 Boehringer Ingelheim Investigational Site
Belgrade
205.452.38101 Boehringer Ingelheim Investigational Site
Kamenitz
205.452.38102 Boehringer Ingelheim Investigational Site
Kragujevac
205.452.38105 Boehringer Ingelheim Investigational Site
Niš

Other trials in Serbia

Australia6 sites

205.452.61006 Boehringer Ingelheim Investigational Site
Adelaide, South Australia
205.452.61004 Boehringer Ingelheim Investigational Site
Box Hill, Victoria
205.452.61003 Boehringer Ingelheim Investigational Site
Footscray, Victoria
205.452.61001 Boehringer Ingelheim Investigational Site
Frankston, Victoria
205.452.61005 Boehringer Ingelheim Investigational Site
Nedlands, Western Australia
205.452.61002 Boehringer Ingelheim Investigational Site
Woodville, South Australia

Other trials in Australia

Mexico6 sites

205.452.52004 Boehringer Ingelheim Investigational Site
Aguascalientes
205.452.52007 Boehringer Ingelheim Investigational Site
Distrito Federal
205.452.52005 Boehringer Ingelheim Investigational Site
Guadalajara
205.452.52001 Boehringer Ingelheim Investigational Site
México
205.452.52002 Boehringer Ingelheim Investigational Site
Monte Rey
205.452.52003 Boehringer Ingelheim Investigational Site
Zona Río

Other trials in Mexico

Colombia5 sites

205.452.57002 Boehringer Ingelheim Investigational Site
Bogotá
205.452.57004 Boehringer Ingelheim Investigational Site
Bogotá
205.452.57005 Boehringer Ingelheim Investigational Site
Bogotá
205.452.57006 Boehringer Ingelheim Investigational Site
Bogotá
205.452.57001 Boehringer Ingelheim Investigational Site
Medellín

Other trials in Colombia

Thailand5 sites

205.452.66004 Boehringer Ingelheim Investigational Site
Chiang Mai
205.452.66003 Boehringer Ingelheim Investigational Site
Hatyai, Songkhla
205.452.66002 Boehringer Ingelheim Investigational Site
Khon Kaen
205.452.66001 Boehringer Ingelheim Investigational Site
Nonthaburi
205.452.66005 Boehringer Ingelheim Investigational Site
Phitsanulok

Other trials in Thailand

New Zealand4 sites

205.452.64004 Boehringer Ingelheim Investigational Site
Christchurch
205.452.64003 Boehringer Ingelheim Investigational Site
Dunedin
205.452.64002 Boehringer Ingelheim Investigational Site
Newtown Wellington NZ
205.452.64001 Boehringer Ingelheim Investigational Site
Tauranga

Other trials in New Zealand

Austria3 sites

205.452.43002 Boehringer Ingelheim Investigational Site
Feldbach
205.452.43003 Boehringer Ingelheim Investigational Site
Hallein
205.452.43005 Boehringer Ingelheim Investigational Site
Thalheim bei Wels

Other trials in Austria

Panama3 sites

205.452.50703 Boehringer Ingelheim Investigational Site
Carrasquilla
205.452.50701 Boehringer Ingelheim Investigational Site
Marbella
205.452.50702 Boehringer Ingelheim Investigational Site
Marbella

Other trials in Panama

Puerto Rico2 sites

205.452.01177 Boehringer Ingelheim Investigational Site
Ponce
205.452.01162 Boehringer Ingelheim Investigational Site
San Juan

Other trials in Puerto Rico

About this study

Official title: A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)

Conditions: Pulmonary Disease, Chronic Obstructive
Being tested: tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
Medical subject headings: Pulmonary Disease, Chronic Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

tiotropium 18 mcgDrug
HandiHaler
tiotropium 1.25 mcg (2 actuations/day)Drug
soft mist inhaler 2 actuations=2 puffs/day
tiotropium 2.5 mcg (2 actuations/day)Drug
soft mist inhaler (2 actuations=2 puffs/day)

Study groups in NCT01126437
Study group	Role	What they receive
tiotropium 2.5 mcg and placebo	Experimental	Patients receive one of the active tiotropium arms daily Receives: Drug: tiotropium 1.25 mcg (2 actuations/day)
tiotropium 18 mcg and placebo	Active comparator	Patients receive one of the active tiotropium arms daily Receives: Drug: tiotropium 18 mcg
tiotropium 5 mcg and placebo	Experimental	Patients receive one of the active tiotropium arms daily Receives: Drug: tiotropium 2.5 mcg (2 actuations/day)

What is being measured

The primary outcome is the main question the study is designed to answer.

Time to All-Cause Mortality
Number of patients with all-cause mortality
Measured: Up to 3 years
Time to First COPD Exacerbation
Defined as "a complex of lower respiratory events/symptoms (increase of new onset) related to the underlying COPD, with duration of three days or more, requiring a change in treatment" where a "complex of lower respiratory event/symptoms" was defined as having at least two of the following: shortness of breath, sputum production (volume), occurrence of purulent sputum, cough, wheezing, chest tightness and where "a required change in treatment" includes the following:Prescription of antibiotics and/or systemic steroids, and/or a newly prescribed maintenance respiratory medication (i.e., bronchodilators including theophyllines).
"Onset of exacerbation" was defined by the onset of first recorded symptom. The "end of exacerbation" was decided by the investigator based on clinical judgement.
Exacerbations were classified as follows:
Mild:a new prescription of maintenance bronchodilator only Moderate:antibiotics or systemic steroids without hospitalization Severe:hospitalization.
Measured: Up to 3 years

Secondary outcomes (7)

Trough FEV1 Over 120 Weeks (in a Substudy of 1370 Patients)
Trough forced expiratory volume in one second (FEV1) over 120 weeks (in a substudy of 1370 patients)
Measured: Up to 3 years
Number of COPD Exacerbations
The number of COPD exacerbations. COPD exacerbation defined as "a complex of lower respiratory events/symptoms (increase of new onset) related to the underlying COPD, with duration of three days or more, requiring a change in treatment" where a "complex of lower respiratory event/symptoms" was defined as having at least two of the following: shortness of breath, sputum production (volume), occurrence of purulent sputum, cough, wheezing, chest tightness and where "a required change in treatment" includes the following:Prescription of antibiotics and/or systemic steroids, and/or a newly prescribed maintenance respiratory medication (i.e., bronchodilators including theophyllines).
Measured: Up to 3 years
Time to First Hospitalization Associated With COPD Exacerbation
The results presented below are for the patients with hospitalizations due to COPD exacerbations.
Measured: Up to 3 years
Number of Hospitalizations Associated With COPD Exacerbation
Total number of hospitalizations associated with COPD exacerbation.
Measured: Up to 3 years
Time to First Moderate to Severe COPD Exacerbation
COPD exacerbation defined as "a complex of lower respiratory events/symptoms (increase of new onset) related to the underlying COPD, with duration of three days or more, requiring a change in treatment" where a "complex of lower respiratory event/symptoms" was defined as having at least two of the following: shortness of breath, sputum production (volume), occurrence of purulent sputum, cough, wheezing, chest tightness and where "a required change in treatment" includes the following:Prescription of antibiotics and/or systemic steroids, and/or a newly prescribed maintenance respiratory medication (i.e., bronchodilators including theophyllines).
Exacerbations classified as follows:
Mild:a new prescription of maintenance bronchodilator only Moderate:antibiotics or systemic steroids without hospitalization Severe:hospitalization.
Results presented below are number of patients with moderate to severe exacerbations.
Measured: Up to 3 years
Time to Onset of First Major Adverse Cardiovascular Event (MACE)
Time to onset of first major adverse cardiovascular event (MACE). MACE was defined as: Fatal event in the system organ classes of cardiac and vascular disorders, Preferred terms: sudden death, cardiac death, sudden cardiac death, Outcome events of myocardial infarction (serious and non-serious), Outcome events of stroke (serious and non-serious) and Outcome events of TIA (serious and non-serious). The results presented below are for the number of patients with MACE.
Measured: Up to 3 years
Time to Death From Major Adverse Cardiovascular Event (MACE)
The results presented below are number of patients with death from MACE.
Measured: Up to 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

May 2010May 2013

First posted19 May 2010 (estimated)
Study startMay 2010
Primary completionMay 2013
Study completionMay 2013

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (5)Papers the sponsor has linked to this study.
Other trials for Pulmonary Disease, Chronic ObstructiveStudies of the same condition, open and under way.
More trials run by Boehringer IngelheimThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Enrolment: 17,183 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01126437
Sponsor's protocol ID: 205.452
Other IDs: 2009-015713-51, 2009
Status last verified: May 2014
First submitted: 6 May 2010
Last updated: 20 Jun 2014
Results posted: Yes, on ClinicalTrials.gov

Publications

Wise RA, Calverley PM, Carter K, Clerisme-Beaty E, Metzdorf N, Anzueto A. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR(R) trial. Int J Chron Obstruct Pulmon Dis. 2018 Feb 14;13:605-616. doi: 10.2147/COPD.S148393. eCollection 2018.
PubMed 29497289
Calverley PMA, Mueller A, Fowler A, Metzdorf N, Wise RA. The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV1/FVC Ratio in Tiotropium Safety and Performance in Respimat Participants. Ann Am Thorac Soc. 2018 Feb;15(2):200-208. doi: 10.1513/AnnalsATS.201703-194OC.
PubMed 28957643
Dahl R, Calverley PM, Anzueto A, Metzdorf N, Fowler A, Mueller A, Wise R, Dusser D. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial. BMJ Open. 2015 Dec 29;5(12):e009015. doi: 10.1136/bmjopen-2015-009015.
PubMed 26715479
Anzueto A, Wise R, Calverley P, Dusser D, Tang W, Metzdorf N, Dahl R. The Tiotropium Safety and Performance in Respimat(R) (TIOSPIR(R)) Trial: Spirometry Outcomes. Respir Res. 2015 Sep 15;16(1):107. doi: 10.1186/s12931-015-0269-4.
PubMed 26369563
Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013 Oct 17;369(16):1491-501. doi: 10.1056/NEJMoa1303342. Epub 2013 Aug 30.
PubMed 23992515

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease

All Pulmonary Disease, Chronic Obstructive trials

Study at a glance

From the registry record, last updated by the sponsor on 20 Jun 2014. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)
ClinicalTrials.gov ID: NCT01126437
Acronym / sponsor ID: 205.452
Conditions: Pulmonary Disease, Chronic Obstructive
Phase: Phase 3
Study type: Interventional
Recruitment status: Completed
Enrolment: 17,183 participants (actual)
Lead sponsor: Boehringer IngelheimIndustry (pharma, biotech, devices)
Study start: May 2010
Primary completion: May 2013 (actual)
Study completion: May 2013 (actual)
First posted: 19 May 2010 (estimated)
Results: Posted 20 Jun 2014

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Number of arms: 3

Arm	Type	Receives
tiotropium 2.5 mcg and placebo	Experimental	Drug: tiotropium 1.25 mcg (2 actuations/day)Patients receive one of the active tiotropium arms daily
tiotropium 18 mcg and placebo	Active comparator	Drug: tiotropium 18 mcgPatients receive one of the active tiotropium arms daily
tiotropium 5 mcg and placebo	Experimental	Drug: tiotropium 2.5 mcg (2 actuations/day)Patients receive one of the active tiotropium arms daily

Who may qualify

Ages: 40 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (7 listed)

All patients must sign an informed consent consistent with International Conference on Harmonization Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions.
Male or female patients 40 years of age or older.
Patients must be current or ex-smokers with a smoking history of ≥10 pack-years. (Patients who have never smoked cigarettes must be excluded)
All patients must have a diagnosis of COPD (P06-12085), and must meet the following criteria: Relatively stable airway obstruction with a post-bronchodilator FEV1 ≤ 70% of predicted normal and post-bronchodilator FEV1 / FVC ≤70%.
Pulmonary function tests (PFTs) were conducted after the inhalation of 400 μg salbutamol / albuterol (preferred), however testing with either 200 μg salbutamol/albuterol or a combination of salbutamol / albuterol with ipratropium bromide (2 to 4 actuations) was acceptable. Other short-acting beta agonists, such as terbutaline, may have been used for the testing. The medication used for the testing was documented. Further, historical data from measurements within the past 6 months either at the site or at a referral site may have been used (see Section 6.2.1 of the CTP, located in Appendix 16.1.1). Subjects were not to have been randomized to the study without the availability of spirometry data at the actual study site.

Key exclusion criteria (22 listed)

Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence the patients ability to participate in the study.
Patients with a recent history (i.e., six months or less) of myocardial infarction.
Patients with any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year.
Hospitalisation for cardiac failure (New York Heart Association (NYHA) Class III or IV) during the past year.
Known active tuberculosis.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
tiotropium 18 mcgHandiHaler	Drug	tiotropium 18 mcg and placebo
tiotropium 1.25 mcg (2 actuations/day)soft mist inhaler 2 actuations=2 puffs/day	Drug	tiotropium 2.5 mcg and placebo
tiotropium 2.5 mcg (2 actuations/day)soft mist inhaler (2 actuations=2 puffs/day)	Drug	tiotropium 5 mcg and placebo

Primary outcome

Time to All-Cause Mortality
Time frame: Up to 3 years
Number of patients with all-cause mortality
Time to First COPD Exacerbation
Time frame: Up to 3 years
Defined as "a complex of lower respiratory events/symptoms (increase of new onset) related to the underlying COPD, with duration of three days or more, requiring a change in treatment" where a "complex of lower respiratory event/symptoms" was defined as having at least two of the following: shortness of breath, sputum production (volume), occurrence of purulent sputum, cough, wheezing, chest tightness and where "a required change in treatment" includes the following:Prescription of antibiotics and/or systemic steroids, and/or a newly prescribed maintenance respiratory medication (i.e., bronchodilators including theophyllines). "Onset of exacerbation" was defined by the onset of first recorded symptom. The "end of exacerbation" was decided by the investigator based on clinical judgement. Exacerbations were classified as follows: Mild:a new prescription of maintenance bronchodilator only Moderate:antibiotics or systemic steroids without hospitalization Severe:hospitalization.

7 secondary outcomes

Trough FEV1 Over 120 Weeks (in a Substudy of 1370 Patients)
Time frame: Up to 3 years
Number of COPD Exacerbations
Time frame: Up to 3 years
Time to First Hospitalization Associated With COPD Exacerbation
Time frame: Up to 3 years
Number of Hospitalizations Associated With COPD Exacerbation
Time frame: Up to 3 years
Time to First Moderate to Severe COPD Exacerbation
Time frame: Up to 3 years
Time to Onset of First Major Adverse Cardiovascular Event (MACE)
Time frame: Up to 3 years
Time to Death From Major Adverse Cardiovascular Event (MACE)
Time frame: Up to 3 years

Results and safety

Results posted to the registry on 20 Jun 2014, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Tiotropium 2.5 mcg and Placebo	5,741	4,400
Tiotropium 5 mcg and Placebo	5,729	4,399
Tiotropium 18 mcg and Placebo	5,713	4,400

Primary outcome: Time to All-Cause Mortality

Time frame: Up to 3 years. Number. Unit: Number of deaths

Measure	Tiotropium 2.5 mcg and Placebo n = 5730	Tiotropium 5 mcg and Placebo n = 5711	Tiotropium 18 mcg and Placebo n = 5694
Value	440 (7.7)	423 (7.4)	439 (7.7)

Tiotropium 5 mcg and Placebo vs Tiotropium 18 mcg and Placebo: Hazard Ratio (HR): 0.957 (95% CI 0.837 to 1.094), Regression, Cox
Tiotropium 2.5 mcg and Placebo vs Tiotropium 18 mcg and Placebo: Hazard Ratio (HR): 0.996 (95% CI 0.872 to 1.136), Regression, Cox

Population analysed: Death analysis set (DAS) including vital status follow-up: This analysis set included all randomized subjects excluding only subjects who were documented as not treated.

Primary outcome: Time to First COPD Exacerbation

Time frame: Up to 3 years. Median (95% Confidence Interval). Unit: days to event

Measure	Tiotropium 2.5 mcg and Placebo n = 5724	Tiotropium 5 mcg and Placebo n = 5705	Tiotropium 18 mcg and Placebo n = 5687
Value	707 (662 to 750)	756 (692 to 816)	719 (672 to 777)

Tiotropium 5 mcg and Placebo vs Tiotropium 18 mcg and Placebo: Hazard Ratio (HR): 0.978 (95% CI 0.928 to 1.032), p = 0.4194, Regression, Cox
Tiotropium 2.5 mcg and Placebo vs Tiotropium 18 mcg and Placebo: Hazard Ratio (HR): 1.016 (95% CI 0.964 to 1.070), p = 0.5593, Regression, Cox
Tiotropium 2.5 mcg and Placebo vs Tiotropium 5 mcg and Placebo: Hazard Ratio (HR): 1.038 (95% CI 0.985 to 1.094), p = 0.1639, Regression, Cox

Population analysed: Treated set (TS, on-treatment only)

7 secondary outcomes are reported in the full results.

Adverse events

Time frame: From the first drug intake up to 30 days after administration. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Tiotropium 2.5 mcg and Placebo	1,932 of 5,724 (33.8%)	1,932 of 5,724 (33.8%)	Not reported
Tiotropium 5 mcg and Placebo	1,876 of 5,705 (32.9%)	1,876 of 5,705 (32.9%)	Not reported
Tiotropium 18 mcg and Placebo	1,928 of 5,687 (33.9%)	1,928 of 5,687 (33.9%)	Not reported

Limitations and caveats (from the sponsor): Prospectively defined outcome events, serious adverse events, adverse events leading to discontinuation, and investigator-determined drug-related adverse events were required for collection in this trial.

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 20 Jun 2014.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 29497289Wise RA, Calverley PM, Carter K, Clerisme-Beaty E, Metzdorf N, Anzueto A. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR(R) trial. Int J Chron Obstruct Pulmon Dis. 2018 Feb 14;13:605-616. doi: 10.2147/COPD.S148393. eCollection 2018.
Derived from this study: PubMed 28957643Calverley PMA, Mueller A, Fowler A, Metzdorf N, Wise RA. The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV1/FVC Ratio in Tiotropium Safety and Performance in Respimat Participants. Ann Am Thorac Soc. 2018 Feb;15(2):200-208. doi: 10.1513/AnnalsATS.201703-194OC.
Derived from this study: PubMed 26715479Dahl R, Calverley PM, Anzueto A, Metzdorf N, Fowler A, Mueller A, Wise R, Dusser D. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial. BMJ Open. 2015 Dec 29;5(12):e009015. doi: 10.1136/bmjopen-2015-009015.
Derived from this study: PubMed 26369563Anzueto A, Wise R, Calverley P, Dusser D, Tang W, Metzdorf N, Dahl R. The Tiotropium Safety and Performance in Respimat(R) (TIOSPIR(R)) Trial: Spirometry Outcomes. Respir Res. 2015 Sep 15;16(1):107. doi: 10.1186/s12931-015-0269-4.
Derived from this study: PubMed 23992515Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013 Oct 17;369(16):1491-501. doi: 10.1056/NEJMoa1303342. Epub 2013 Aug 30.
Related InfoLink provided by the sponsor.
Related InfoLink provided by the sponsor.

Related trials for Pulmonary Disease, Chronic Obstructive

Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Boehringer Ingelheim study chair

Boehringer Ingelheim

1,191 sites in 51 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1,191 sites in United States, Germany, France, Russia, Canada and 46 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 20 Jun 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to All-Cause Mortality (time frame: Up to 3 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01126437, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jun 2014.